| Dokumendiregister | Terviseamet |
| Viit | 13.2-7/24/2927-1 |
| Registreeritud | 18.03.2024 |
| Sünkroonitud | 26.03.2024 |
| Liik | Sissetulev dokument |
| Funktsioon | 13.2 Nakkushaiguste labor |
| Sari | 13.2-7 NHL kirjavahetus |
| Toimik | 13.2-7/2024 |
| Juurdepääsupiirang | Avalik |
| Juurdepääsupiirang | |
| Adressaat | The Francis crick Institute |
| Saabumis/saatmisviis | The Francis crick Institute |
| Vastutaja | Irina Odintsova (TA, Peadirektori asetäitja (2) vastutusvaldkond, Rahvatervise labor, Nakkushaiguste labor) |
| Originaal | Ava uues aknas |
From: Monica Galiano <[email protected]>
Sent: Fri, 15 Mar 2024 16:29:58 +0000
To: Janne Pullat <[email protected]>; Irina Eero <[email protected]>; Liisa Lilje <[email protected]>; Johanna Kristina Tamm <[email protected]>
Cc: whocc <[email protected]>; "ZHANG; Wenqing" <[email protected]>; "Dmitriy Pereyaslov" <[email protected]>; "SAMAAN; Magdi" <[email protected]>; "NAHAPETYAN; Karen" <[email protected]>; "WIDDOWSON; Marc-alain" <[email protected]>
Subject: Country report: Estonia
Dear Janne, Irina, Liisa and Johanna,
I hope you are well. Here are the results of the analyses of the influenza specimens you kindly shared with us for characterisation from Estonia in February and May 2023. Apologies for the delay in preparing this report as we had to deal with some staff shortages.
Along with the analyses, we have also included a high-level summary of influenza circulation and evolution during the South hemisphere influenza season of 2023. We will be preparing another report for samples received during the North hemisphere influenza season 2023-2024 soon.
Should you need any additional information, please don’t hesitate to contact us, we will be very happy to assist.
I look forward to continuing to work closely with you and thank you again for your support and collaboration.
With very best wishes,
Monica
On behalf of the WIC team
Dr Monica Galiano
Head of Molecular Testing and Genomics
WHO Collaborating Centre for Reference and Research on Influenza,
The Francis Crick Institute
1 Midland Road
London NW1 1AT
UK
Tel: +44 203 796 0563
Email: [email protected]
The Francis Crick Institute Limited is a registered charity in England and Wales no. 1140062 and a company registered in England and Wales no. 06885462, with its registered office at 1 Midland Road London NW1 1AT
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.
Country Report: Estonia Worldwide Influenza Centre, WHO CC for Reference and Research on Influenza, The Francis
Crick Institute, 1 Midland Road, NW1 1AT
September 2022 to July 2023
Prof. Nicola Lewis (Director ‑ WIC)
Dr. Ruth Harvey (Deputy Director)
Dr. Monica Galiano (Head of Molecular Testing and Genomics)
Dr. Alex Byrne
Dr. Zheng Xiang
Ms. Christine Carr, Ms. Burcu Ermetal
Dr. Karen Cross, Ms. Aine Rattigan
Ms. Alice Lilley, Mr. Michael Bennett
Ms. Chandrika Halai, Ms. Becky Clark, Mr. Lorin Adams
Dr. Tanya Mikaiel, Ms Abi Lofts, Dr. Alize Proust
Tel:0203 796 0563 (WIC) or [email protected]
Email: [email protected]; [email protected]; [email protected];
Formore informationaboutwhatwehaveobservedover the last twelvemonthsplease seeour reports for February 2023 and September 2023. All of our reports since 2003 are available at https://www.crick.ac.uk/partnerships/w orldwide‑influenza‑centre/annual‑and‑interim‑reports
1
Influenza by type/subtype: Geographical distribution of seasonal influenza viruses with collection dates from February 2023 through to September 2023 as deposited in GISAID, coloured by Type/subtype. Geographic markers scaled to detection proportions.
Globally, influenza detections declined through the reporting period. However the relative proportions of A/H1N1, A/H3N2 andB/Victoria varied by geographic region as indicated by the different colours in the pie charts by country.
2
Genetic diversity: Plots showing genetic diversity of A/H1N1, A/H3N2 and B/Victoria that underwent sequencing during the reporting period. A(global) B(WHO region)
3
Phylogenetic analyses: A/H1N1
Globally 6B.1A.5a.2a and 6B.1A.5a.2a.1 clade viruses both continued to circulate with differing relative propor‑ tions depending on region.
Clade 5a.2a viruses predominated since 1st February in Africa, the Eastern Mediterranean, and South East Asia, albeit with few viruses detected.
In Europe,Western Pacific and the Americas both 5a.2a and 5a.2a.1 viruseswere detected, with 5a.2a viruses being the larger proportion.
Within 5a.2a clade, A/Sydney/5/2021‑like viruses were detected but in theminority. We note three subgroups; one detected in Australia and Europe, represented by A/Sydney/175/2022; a second detected in South East Asia (S83P, S85P, H273Q, V321I) and the other represented by A/Washington/22/2023 or A/Washington/24/2022 (A73T, A141E, V152I, S190I).
The larger 5a.2a group has split into three groups defined by the following references, with some additional amino acid substitutions: A/Maine/10/2022 ‑like (A48P), A/Netherlands/10468/2023‑like (I418V, D269N, P137S) and the remaining group, without a potential CVV or reference, defined by I418V.
Within 5a.2a.1 clade (P137S, T277A, E356D) there are twomain groups of viruses ‑ either A/Wisconsin/67/2022‑like or A/Victoria/4897/2022‑like (with T216A).
Themajority of A/H1N1 virus HA sequences fromEstonia clusteredwithin clade 5a.2a, with a few sequences groupedwithin clade 5a.2a.1.
Maximum likelihood phylogenetic tree of the H1 HA gene Maximum likelihood phylogenetic tree inferred using Iqtree2 from HA sequence data generated at the WIC. Anno‑ tation of amino acids substitutions was performed with Treetime ancestral reconstruction. References and CVVs are marked as Cell or Egg. Virus names are colored by collection month.
4
5
Phylogenetic analyses: H3N2
Clade 3C.2a1b.2a.2 predominated since 1st February in all geographic regions where H3N2 circulated. We ob‑ served continued co‑circulation of multiple genetic clades ‑ however 2a.1b, 2a.3a.1 and 2b clades were the most frequently detected.
Viruses from clade 2b (E50K, F79V, I140K) are split into three subclades: one with I242M; a second represented by A/Florida/50/2022, A/Puerto Rico/31/2022 as potential CVVs; and a third subclade (S262N)with twogroups: viruses from Europe and Japan (R33Q) and viruses from Europe represented by A/Montana/08/2023 (T135Awith potential loss of glycosylation).
Viruses from clade 2a.1b (I140K, R299K) were detected in Europe and South Africa, represented by A/Catalonia/NSVH161512067/2022.
Clade 2a.3a.1 viruseswere detectedworldwide, characterised by I140Kwith a subclade showingN122D (loss of gly‑ cosylation), represented by A/New York/66/2022 and another subclade with I25V, V347M, I418V, detected in China and the US.
A/H3N2 virus HA sequences from Estonia clustered in similar proportions within clades 2b and 2a.1b.
Maximum likelihood phylogenetic tree of the H3 HA gene. Maximum likelihood phylogenetic tree inferred using Iqtree2 from HA sequence data generated at the WIC. Anno‑ tation of amino acids substitutions was performed with Treetime ancestral reconstruction. References and CVVs are marked as Cell or Egg. Virus names are colored by collection month.
6
7
Phylogenetic analyses:
Influenza B viruses B/Victoria lineage
Clade V1A.3a.2 viruses predominated since 1st February 2023 in geographic regions where B/Victoria‑lineage viruses were detected.
No Clade V1A.3 viruses were detected since 1st February 2023.
All B/Victoria lineage HA sequences from Estonia groupedwithin clade V1A.3a.2.
B/Yamagata lineage No B/Yamagata lineage viruses have been detected since March 2020.
Maximum likelihood phylogenetic tree of the B/Victoria lineage HA gene Maximum likelihood phylogenetic tree inferred using Iqtree2 from HA sequence data generated at the WIC. Anno‑ tation of amino acids substitutions was performed with Treetime ancestral reconstruction. References and CVVs are marked as Cell or Egg. Virus names are colored by collection month.
8
9
Phenotypic analyses Haemagglutination inhibition (HI) assay data: ferret antisera raised against vaccine recommendations
H1 Summary Some HI titre fold reductions were observed against the SH2023 vaccine strain (A/Sydney/5/21 cell 5a.2a), espe‑ cially when test viruses are 5a.2a.1, whereas the cell based NH 2023‑24 cell based strain (A/Victoria/4897/2022) recognises both 5a.2a and 5a.2a.1 well.
Egg‑based A/Victoria/4897/2022 recognises both 5a.2a and 5a.2a.1 test viruses well.
H3 Summary For clade 2a.2 viruses we observed that, where we have titrations, the post‑infection antisera raised against new reference viruses discriminated antigenic properties among the different genetic subgroups.
In HI assays, the egg‑based A/Darwin/9/21 vaccine strain is showing reduced recognition of 2a.1b and 2a.3a.1 groups and amore dramatic loss in recognition for test viruses in the 2b clade.
In MN assay the egg based A/Darwin/9/21 vaccine strain is showing significantly reduced recognition to all other clades of test viruses.
A/Albania/289813/2022 (2a.3a.1) shows good recognition of test viruses in its own clade, but this antiserum does not recognise viruses in clade 2b at all.
A/Slovenia/8720/2022 (2a.1) shows good recognition of 2a.1b and 2a.3a.1 viruses, with some lower recognition of 2b viruses.
Influenza B summary B/Victoria lineage: All V1A.3a.2viruses testedwerewell‑recognisedbyantisera raisedagainstB/Austria/1359417/2021 vaccine virus.
Antiviral susceptibility All tested viruses were susceptible to neuraminidase inhibitors (NAI) by phenotypic testing and no geneticmarkers for reduced inhibition by NAIs were identified in NA sequences derived from clinical specimens.
For all viruses where PA gene sequencing was successful, no markers associated with reduced inhibition by balox‑ avir marboxil were identified.
10
HI Tables: H1
Table H1-10. Antigenic analyses of influenza A(H1N1)pdm09 viruses (2023-05-23)
Viruses Other Collection Passage A/G-M A/G-M A/Ghana A/Lyon A/Denmark IVR-215 A/Sydney A/Sydney A/Norway A/Norway/ A/Victoria/ IVR-238 information date history SWL1536/19 SWL1536/19 1894/21 820/21 3280/19 A/Vic/2570/19 5/21 5/21 25089/22 31694/2022 4897/2022 A/Vic/4897/22
Passage history MDCK Egg Egg Egg MDCK Egg MDCK Egg MDCK Egg MDCK Egg Ferret number F09/20 F12/20 F02/22 F06/22 F28/20 F37/21 F46/22 F04/22 F38/22 F48/22 F05/23 F07/23 Genetic group 5a.1 5a.1 5a.1 5a.1 5a.2 5a.2 5a.2a 5a.2a 5a.2a.1 5a.2a.1 5a.2a.1 5a.2a.1
REFERENCE VIRUSES A/Guangdong-Maonan/SWL1536/2019 5a.1 2019-06-17 C2/MDCK1 2560 1280 640 320 40 <40 <40 40 40 <40 <40 80 A/Guangdong-Maonan/SWL1536/2019 5a.1 2019-06-17 E3/E2 640 640 640 320 <40 40 <40 <40 <40 <40 <40 40 A/Ghana/1894/2021 5a.1 2021-07-21 E2/E1 2560 1280 640 160 40 80 40 40 40 <40 40 80 A/Lyon/820/2021 5a.1 2021-11-16 E1/E2 320 160 160 320 40 40 <40 <40 <40 <40 <40 160 A/Denmark/3280/2019 5a.2 2019-11-10 MDCK4/MDCK6 40 40 <40 40 1280 1280 640 1280 1280 320 1280 640 IVR-215 (A/Victoria/2570/2019) 5a.2 2018-11-22 E4/D7/E2 160 80 40 80 640 1280 640 640 640 320 640 1280 A/Sydney/5/2021 clone 3.4.1 5a.2a 2021-10-16 MDCK3/MDCK3 40 40 <40 <40 1280 1280 1280 1280 1280 640 1280 1280 A/Sydney/5/2021 pooled clones 10-10 5a.2a 2022-10-31 E3/E3 80 80 40 40 640 1280 1280 1280 1280 320 1280 2560 A/Norway/25089/2022 5a.2a.1 2022-06-15 MDCK3 <40 <40 <40 <40 640 640 640 640 1280 640 1280 1280 A/Norway/31694/2022 5a.2a.1 2022-09-24 E3/E1 10-3 <40 <40 <40 <40 320 640 320 640 640 320 1280 640 A/Victoria/4897/2022 5a.2a.1 2022-10-02 SIAT2/MDCK2 40 <40 <40 <40 1280 1280 1280 1280 2560 1280 2560 1280 IVR-238 (A/Victoria/4897/2022) 5a.2a.1 2022-10-02 E3/D6/E1 10-6 80 80 40 80 1280 1280 1280 1280 1280 640 1280 2560
TEST VIRUSES
A/Antsirabe/07452/2022 5a.2a 2022-12-05 MDCK1 40 40 <40 <40 640 640 640 640 640 320 1280 640 A/Lisboa/756/2022 5a.2a 2022-12-19 MDCK1 40 40 <40 <40 640 1280 1280 1280 1280 640 1280 1280 A/Antsirabe/07646/2022 5a.2a 2022-12-19 MDCK1 40 40 <40 <40 320 640 640 640 640 320 640 640 A/MountLebanon/2884/2022 5a.2a 2022-12-20 MDCK1 40 40 <40 <40 1280 1280 1280 1280 1280 640 1280 1280 A/Albania/290498/2023 5a.2a 2023-01-04 MDCK3 40 40 <40 <40 640 640 640 1280 1280 320 1280 1280 A/Albania/290464/2023 5a.2a 2023-01-04 MDCK2 80 40 <40 <40 1280 2560 1280 2560 1280 640 2560 2560 A/North Lebanon/S0043/2023 5a.2a 2023-01-04 MDCK1 40 40 <40 <40 640 1280 1280 1280 640 320 640 1280 A/Montenegro/102793/2023 5a.2a 2023-01-10 MDCK1 80 80 <40 <40 1280 1280 2560 2560 1280 640 2560 2560 A/North Lebanon/S0063/2023 5a.2a 2023-01-11 MDCK1 40 <40 <40 <40 320 640 320 640 320 160 640 640 A/Estonia/KL262/2023 5a.2a 2023-02-14 MDCK1 40 40 <40 <40 640 1280 640 1280 640 320 1280 1280 A/Estonia/173456/2023 5a.2a 2023-02-14 MDCK1 40 40 <40 <40 640 640 640 1280 640 320 640 1280 A/Estonia/173432/2023 5a.2a 2023-02-14 MDCK1 40 40 <40 <40 640 1280 640 1280 640 320 1280 1280 A/Estonia/173557/2023 5a.2a 2023-02-21 MDCK1 40 <40 <40 <40 320 640 320 640 320 320 640 640 A/Estonia/173652/2023 5a.2a 2023-03-02 MDCK1 40 40 <40 <40 1280 1280 1280 2560 1280 640 1280 2560 A/Estonia/173780/2023 5a.2a 2023-03-07 MDCK1 40 40 <40 <40 640 1280 1280 1280 640 320 1280 1280 A/Slovenia/812/2023 5a.2a 2023-03-13 MDCKf0/MDCK1 40 40 <40 <40 640 640 640 640 640 320 640 640 A/Slovenia/836/2023 5a.2a 2023-03-15 MDCKf0/MDCK1 40 40 40 40 640 1280 1280 1280 640 320 1280 640 A/Estonia/174171/2023 5a.2a 2023-04-14 MDCK1 40 40 <40 <40 640 1280 640 1280 640 320 1280 2560 A/Albania/290245/2022 5a.2a MDCK3 <40 <40 <40 <40 80 160 160 320 320 160 320 320 A/Ireland/79395/2022 5a.2a.1 2022-12-17 MDCK3 <40 <40 <40 <40 160 320 160 160 320 160 640 160 A/Lisboa/733/2022 5a.2a.1 MDCK1 <40 <40 <40 <40 640 640 640 1280 1280 640 1280 640
Vaccine Vaccine Vaccine < relates to the lowest dilution of antiserum used NH 2020-21 SH 2021 NH 2023-2024 ND = Not Done NH 2021-22
SH 2022 NH 2022-23
Haemagglutination inhibition titre
Post-infection ferret antiserum
Vaccine SH 2023
11
Table H1-11. Antigenic analyses of influenza A(H1N1)pdm09 viruses (2023-06-01)
Viruses Other Collection Passage A/G-M A/G-M A/Ghana A/Lyon A/Denmark IVR-215 A/Sydney A/Sydney A/Norway A/Norway/ A/Victoria/ IVR-238 information date history SWL1536/19 SWL1536/19 1894/21 820/21 3280/19 A/Vic/2570/19 5/21 5/21 25089/22 31694/2022 4897/2022 A/Vic/4897/22
Passage history MDCK Egg Egg Egg MDCK Egg MDCK Egg MDCK Egg MDCK Egg Ferret number F09/20 F12/20 F02/22 F06/22 F28/20 F37/21 F46/22 F04/22 F38/22 F48/22 F05/23 F07/23 Genetic group 5a.1 5a.1 5a.1 5a.1 5a.2 5a.2 5a.2a 5a.2a 5a.2a.1 5a.2a.1 5a.2a.1 5a.2a.1
REFERENCE VIRUSES A/Guangdong-Maonan/SWL1536/2019 5a.1 2019-06-17 C2/MDCK1 2560 1280 1280 320 40 80 40 40 40 <40 <40 160 A/Guangdong-Maonan/SWL1536/2019 5a.1 2019-06-17 E3/E2 1280 1280 640 320 40 80 <40 40 <40 <40 <40 80 A/Ghana/1894/2021 5a.1 2021-07-21 E2/E1 2560 2560 1280 320 80 160 40 80 40 <40 <40 80 A/Lyon/820/2021 5a.1 2021-11-16 E1/E2 640 320 320 640 40 80 40 40 40 <40 <40 320 A/Denmark/3280/2019 5a.2 2019-11-10 MDCK4/MDCK6 160 160 80 160 2560 2560 1280 2560 1280 640 2560 2560 IVR-215 (A/Victoria/2570/2019) 5a.2 2018-11-22 E4/D7/E2 160 80 40 80 1280 1280 640 1280 1280 320 640 1280 A/Sydney/5/2021 clone 3.4.1 5a.2a 2021-10-16 MDCK3/MDCK3 160 160 40 40 1280 2560 2560 2560 1280 640 1280 1280 A/Sydney/5/2021 pooled clones 10-10 5a.2a 2022-10-31 E3/E3 80 40 40 40 640 1280 640 1280 1280 320 1280 1280 A/Norway/25089/2022 5a.2a.1 2022-06-15 MDCK3 40 80 <40 <40 1280 1280 1280 1280 1280 1280 2560 1280 A/Norway/31694/2022 5a.2a.1 2022-09-24 E3/E1 10-3 40 80 40 80 640 1280 640 1280 1280 640 2560 1280 A/Victoria/4897/2022 5a.2a.1 2022-10-02 SIAT2/MDCK2 80 80 <40 40 1280 2560 2560 2560 2560 1280 2560 1280 IVR-238 (A/Victoria/4897/2022) 5a.2a.1 2022-10-02 E3/D6/E1 10-6 80 80 40 80 640 1280 1280 1280 1280 640 1280 2560
TEST VIRUSES
A/Macedonia/364/2022 5a.2a 2022-12-19 MDCK1 80 40 <40 40 640 1280 640 640 640 320 1280 640 A/AlmatyRegion/12162/2022 5a.2a 2022-12-20 MDCK1 80 160 40 80 2560 2560 2560 2560 2560 640 2560 2560 A/Estonia/KL7228/2022 5a.2a 2022-12-20 MDCK1 40 40 <40 40 640 1280 640 1280 640 320 640 1280 A/Estonia/172548/2022 5a.2a 2022-12-27 MDCK1 80 80 40 80 1280 2560 2560 2560 2560 640 2560 2560 A/Slovenia/127/2023 5a.2a 2023-01-09 SIAT0/MDCK1 80 80 <40 40 1280 1280 1280 1280 1280 320 1280 1280 A/Slovenia/124/2023 5a.2a 2023-01-09 MDCK0/MDCK1 40 40 <40 <40 640 1280 640 1280 640 320 640 1280 A/Serbia/206/2023 5a.2a 2023-01-10 MDCK1 160 160 40 80 2560 2560 2560 2560 2560 640 2560 2560 A/Serbia/260/2023 5a.2a 2023-01-11 MDCK1 80 160 40 80 2560 2560 2560 5120 2560 640 2560 2560 A/Serbia/193/2023 5a.2a 2023-01-11 MDCK1 160 160 40 80 2560 2560 2560 2560 2560 640 5120 2560 A/Macedonia/70/2023 5a.2a 2023-01-13 MDCK1 80 80 40 80 1280 2560 2560 2560 2560 640 2560 2560 A/Estonia/172881/2023 5a.2a 2023-01-15 MDCK1 <40 <40 <40 <40 320 640 640 640 640 160 640 640 A/Slovenia/191/2023 5a.2a 2023-01-16 MDCK0/MDCK1 80 80 40 40 1280 2560 1280 2560 2560 640 2560 2560 A/Slovenia/187/2023 5a.2a 2023-01-16 SIAT0/MDCK1 80 80 40 40 1280 1280 1280 1280 1280 640 2560 1280 A/Estonia/172997/2023 5a.2a 2023-01-18 MDCK1 40 40 <40 40 1280 2560 1280 2560 1280 640 2560 2560 A/Macedonia/91/2023 5a.2a 2023-01-18 MDCK1 80 80 40 40 1280 2560 1280 2560 1280 640 2560 2560 A/Macedonia/374/2023 5a.2a 2023-01-18 MDCK1 80 80 40 80 2560 2560 2560 2560 2560 640 2560 2560 A/Slovenia/245/2023 5a.2a 2023-01-19 MDCKf0/MDCK1 40 40 <40 40 640 1280 1280 1280 640 320 1280 1280 A/Estonia/173037/2023 5a.2a 2023-01-23 MDCK1 80 80 40 40 1280 2560 2560 2560 2560 640 2560 2560 A/Slovenia/281/2023 5a.2a 2023-01-23 SIAT0/MDCK1 80 40 40 40 1280 1280 1280 1280 1280 640 1280 1280 A/Slovenia/275/2023 5a.2a 2023-01-23 MDCK0/MDCK1 80 80 40 40 1280 2560 1280 1280 1280 640 1280 1280 A/Slovenia/271/2023 5a.2a 2023-01-23 SIAT0/MDCK1 40 40 <40 <40 640 1280 640 1280 640 320 1280 1280 A/Slovenia/375/2023 5a.2a 2023-01-31 SIAT0/MDCK1 80 80 40 40 1280 2560 1280 1280 1280 640 1280 1280 A/Slovenia/363/2023 5a.2a 2023-01-31 MDCK0/MDCK1 40 40 <40 40 1280 1280 1280 1280 1280 640 1280 1280 A/Slovenia/427/2023 5a.2a 2023-02-08 SIAT0/MDCK1 80 80 40 40 1280 1280 1280 1280 1280 640 1280 1280 A/Slovenia/438/2023 5a.2a 2023-02-09 MDCK0/MDCK1 40 80 <40 40 1280 1280 1280 1280 1280 640 1280 1280 A/Estonia/KL318/2023 5a.2a 2023-02-27 MDCK2 80 80 40 80 2560 2560 2560 2560 2560 1280 2560 2560 A/Slovenia/656/2023 5a.2a 2023-03-01 MDCKf0/MDCK1 80 80 40 40 1280 2560 2560 2560 1280 640 1280 2560 A/Slovenia/655/2023 5a.2a 2023-03-01 MDCKf0/MDCK1 80 80 40 40 1280 2560 1280 2560 1280 640 1280 2560 A/Slovenia/714/2023 5a.2a 2023-03-06 SIAT0/MDCK1 80 80 <40 40 1280 2560 1280 2560 1280 640 2560 1280 A/Slovenia/742/2023 5a.2a 2023-03-08 SIAT0/MDCK1 160 80 <40 40 1280 1280 1280 1280 1280 640 1280 1280 A/Slovenia/776/2023 5a.2a 2023-03-09 MDCKf0/MDCK1 40 40 <40 40 640 1280 1280 1280 1280 320 1280 1280 A/Slovenia/801/2023 5a.2a 2023-03-13 MDCKf0/MDCK1 80 40 <40 40 1280 1280 1280 1280 1280 320 1280 1280 A/Bulgaria/1762/2023 5a.2a 2023-03-14 MDCK2/MDCK1 80 80 40 40 1280 2560 2560 2560 2560 640 2560 2560 A/Bulgaria/1926/2023 5a.2a 2023-04-04 MDCK2/MDCK1 80 80 40 80 1280 2560 2560 2560 2560 640 2560 2560 A/Serbia/315/2023 5a.2a.1 2023-01-09 MDCK1 40 40 <40 <40 1280 1280 1280 1280 2560 1280 2560 1280 A/Serbia/185/2023 5a.2a.1 2023-01-09 MDCK2 40 80 <40 40 2560 2560 1280 2560 2560 1280 5120 2560 A/Serbia/313/2023 5a.2a.1 2023-01-10 MDCK1 80 80 <40 40 1280 1280 640 1280 2560 1280 2560 1280
Vaccine Vaccine Vaccine < relates to the lowest dilution of antiserum used NH 2020-21 SH 2021 NH 2023-2024 ND = Not Done NH 2021-22
SH 2022 NH 2022-23
Haemagglutination inhibition titre
Post-infection ferret antiserum
Vaccine SH 2023
12
Table H1-17. Antigenic analyses of influenza A(H1N1)pdm09 viruses (2023-07-25)
Viruses Other Collection Passage A/G-M IVR-215 A/Sydney A/Sydney A/Victoria/ IVR-238 A/Wisconsin/ information date history SWL1536/19 A/Vic/2570/19 5/21 5/21 4897/2022 A/Vic/4897/22 67/2022
Passage history Egg Egg MDCK Egg MDCK Egg MDCK Ferret number F12/20 F37/21 F46/22 F04/22 F05/23 F07/23 F17/23 Genetic group 5a.1 5a.2 5a.2a 5a.2a 5a.2a.1 5a.2a.1 5a.2a.1
REFERENCE VIRUSES A/Guangdong-Maonan/SWL1536/2019 5a.1 2019-06-17 E3/E2 1280 40 <40 40 <40 40 <40 IVR-215 (A/Victoria/2570/2019) 5a.2 2018-11-22 E4/D7/E2 80 1280 640 640 640 1280 320 A/Sydney/5/2021 clone 3.4.1 5a.2a 2021-10-16 MDCK3/MDCK3 80 1280 1280 1280 1280 1280 1280 A/Sydney/5/2021 pooled clones 10-10 5a.2a 2022-10-31 E3/E3 80 1280 1280 1280 1280 2560 640 A/Victoria/4897/2022 5a.2a.1 2022-10-02 SIAT2/MDCK2 40 1280 1280 1280 2560 1280 1280 IVR-238 (A/Victoria/4897/2022) 5a.2a.1 2022-10-02 E3/D6/E1 10-6 40 1280 1280 2560 2560 2560 640 A/Wisconsin/67/2022 5a.2a.1 2022-10-25 MDCK2 40 640 640 1280 2560 1280 1280
TEST VIRUSES
A/Hungary/37/2023 5a.2a 2023-01-26 MDCK1/MDCK1 40 1280 1280 1280 1280 1280 640 A/Hungary/34/2023 5a.2a 2023-01-30 MDCK1/MDCK1 40 1280 640 1280 640 1280 640 A/Norway/1811/2023 5a.2a 2023-01-31 MDCK2 40 1280 1280 1280 1280 1280 640 A/Estonia/173320/2023 5a.2a 2023-02-05 MDCK1 40 1280 1280 1280 1280 1280 640 A/Estonia/173321/2023 5a.2a 2023-02-07 MDCK1 40 1280 1280 1280 1280 1280 640 A/Hungary/66/2023 5a.2a 2023-02-20 MDCK1/MDCK1 80 2560 1280 2560 2560 2560 1280 A/Ireland/15762/2023 5a.2a 2023-03-06 MDCK2 40 1280 1280 2560 2560 1280 640 A/Ireland/16836/2023 5a.2a 2023-03-09 MDCK2 80 1280 1280 2560 2560 2560 1280 A/Ireland/16739/2023 5a.2a 2023-03-10 MDCK2 40 1280 1280 1280 1280 1280 640 A/Hungary/116/2023 5a.2a 2023-03-29 MDCK1/MDCK1 80 2560 1280 2560 2560 2560 1280 A/Serbia/2737/2023 5a.2a 2023-03-29 C2/MDCK1 40 640 640 640 640 640 320
Vaccine Vaccine Vaccine Vaccine < relates to the lowest dilution of antiserum used NH 2020-21 SH 2021 NH 2023-24 NH 2023-24 ND = Not Done NH 2021-22
SH 2022 NH 2022-23
Vaccine SH 2023
13
Table H1-18. Antigenic analyses of influenza A(H1N1)pdm09 viruses (2023-08-01) NEW
Viruses Other Collection Passage A/G-M IVR-215 A/Sydney A/Sydney A/Victoria/ A/Victoria/ IVR-238 A/Wisconsin/ information date history SWL1536/19 A/Vic/2570/19 5/21 5/21 4897/2022 4897/2022 A/Vic/4897/22 67/2022
Passage history Egg Egg MDCK Egg MDCK MDCK Egg MDCK Ferret number F12/20 F37/21 F46/22 F04/22 F05/23 F22/23 F07/23 F17/23 Genetic group 5a.1 5a.2 5a.2a 5a.2a 5a.2a.1 5a.2a.1 5a.2a.1 5a.2a.1
REFERENCE VIRUSES A/Guangdong-Maonan/SWL1536/2019 5a.1 2019-06-17 E3/E2 1280 80 <40 <40 <40 <40 40 <40 IVR-215 (A/Victoria/2570/2019) 5a.2 2018-11-22 E4/D7/E2 80 1280 640 640 640 640 640 320 A/Sydney/5/2021 clone 3.4.1 5a.2a 2021-10-16 MDCK3/MDCK3 40 1280 640 1280 1280 640 1280 640 A/Sydney/5/2021 pooled clones 10-10 5a.2a 2022-10-31 E3/E2 40 640 640 1280 640 320 1280 320 A/Victoria/4897/2022 5a.2a.1 2022-10-02 SIAT2/MDCK2 40 1280 1280 2560 2560 2560 1280 2560 IVR-238 (A/Victoria/4897/2022) 5a.2a.1 2022-10-02 E3/D6/E1 10-6 40 640 640 1280 2560 640 2560 640 A/Wisconsin/67/2022 5a.2a.1 2022-10-25 MDCK2 40 1280 640 1280 2560 1280 1280 1280
TEST VIRUSES A/Parma/11/2023 5a.2a 2023-01-27 MDCK3/MDCK1 <40 640 320 320 320 320 640 320 A/Parma/14/2023 5a.2a 2023-01-31 MDCK3/MDCK1 <40 640 320 640 640 320 640 640 A/FVG-Trieste/114/2023 5a.2a 2023-02-03 MDCK3/MDCK1 <40 640 320 640 640 320 640 320 A/FVG-Gorizia/113/2023 5a.2a 2023-02-03 MDCK3/MDCK1 <40 640 640 640 640 320 640 320 A/FVG-Trieste/116/2023 5a.2a 2023-02-07 MDCK3/MDCK1 40 1280 1280 1280 1280 1280 1280 640 A/FVG-Trieste/115/2023 5a.2a 2023-02-07 MDCK3/MDCK1 <40 1280 640 640 640 320 640 320 A/Estonia/173338/2023 5a.2a 2023-02-09 MDCK2 40 1280 640 1280 640 640 1280 320 A/Belgium/S1341/2023 5a.2a 2023-02-09 MDCK1/MDCK1 40 2560 1280 2560 1280 640 1280 640 A/Belgium/S1330/2023 5a.2a 2023-02-12 MDCK1/MDCK1 <40 1280 640 1280 640 640 1280 320 A/Belgium/G0207/2023 5a.2a 2023-02-13 MDCK1/MDCK1 40 1280 640 1280 1280 640 640 640 A/Belgium/S1391/2023 5a.2a 2023-02-16 MDCK1/MDCK1 40 1280 1280 640 640 640 640 640 A/Belgium/S1354/2023 5a.2a 2023-02-17 MDCK1/MDCK1 40 1280 640 1280 1280 640 640 640 A/Belgium/S1785/2023 5a.2a 2023-02-19 MDCK1/MDCK1 <40 640 640 1280 1280 640 1280 640 A/Belgium/G0248/2023 5a.2a 2023-03-06 MDCK1/MDCK1 40 1280 1280 1280 1280 1280 1280 640 A/Kyiv/1996/2023 5a.2a 2023-03-10 MDCK3/MDCK1 40 2560 2560 2560 2560 1280 2560 1280 A/Serbia/2348/2023 5a.2a 2023-03-14 C1/MDCK1 40 1280 1280 1280 1280 640 1280 640 A/Belgium/S1403/2023 5a.2a 2023-03-14 MDCK1/MDCK1 40 1280 640 640 640 640 640 640 A/Belgium/S1363/2023 5a.2a 2023-03-14 MDCK1/MDCK1 80 1280 1280 1280 2560 1280 1280 640 A/Belgium/S1357/2023 5a.2a 2023-03-14 MDCK1/MDCK1 40 2560 1280 2560 2560 1280 1280 1280 A/Belgium/S1336/2023 5a.2a 2023-03-14 MDCK1/MDCK1 40 1280 1280 1280 1280 1280 1280 640 A/Belgium/S1333/2023 5a.2a 2023-03-14 MDCK1/MDCK1 40 640 640 640 640 640 640 320 A/Belgium/S1331/2023 5a.2a 2023-03-14 MDCK1/MDCK1 40 1280 1280 1280 1280 640 1280 640 A/Belgium/G0310/2023 5a.2a 2023-04-04 MDCK1/MDCK1 40 2560 1280 2560 2560 1280 1280 1280 A/Belgium/G0316/2023 5a.2a 2023-04-06 MDCK1/MDCK1 40 1280 1280 1280 1280 640 1280 640 A/Belgium/S1188/2023 5a.2a.1 2023-02-08 MDCK1/MDCK1 <40 640 640 640 1280 1280 640 640 A/Belgium/S1332/2023 5a.2a.1 2023-02-12 MDCK1/MDCK1 40 1280 640 640 1280 1280 640 640
Vaccine Vaccine Vaccine < relates to the lowest dilution of antiserum used NH 2020-21 SH 2021 NH 2023-24 ND = Not Done NH 2021-22
SH 2022 NH 2022-23
Vaccine SH 2023
14
Table H1-19. Antigenic analyses of influenza A(H1N1)pdm09 viruses (2023-08-08)
Viruses Other Collection Passage A/G-M IVR-215 A/Sydney A/Sydney A/Victoria/ IVR-238 A/Wisconsin/ information date history SWL1536/19 A/Vic/2570/19 5/21 5/21 4897/2022 A/Vic/4897/22 67/2022
Passage history Egg Egg MDCK Egg MDCK Egg MDCK Ferret number F12/20 F37/21 F46/22 F04/22 F05/23 F07/23 F17/23 Genetic group 5a.1 5a.2 5a.2a 5a.2a 5a.2a.1 5a.2a.1 5a.2a.1
REFERENCE VIRUSES A/Guangdong-Maonan/SWL1536/2019 5a.1 2019-06-17 E3/E2 1280 80 <40 <40 <40 40 <40 IVR-215 (A/Victoria/2570/2019) 5a.2 2018-11-22 E4/D7/E2 80 1280 320 640 640 640 320 A/Sydney/5/2021 clone 3.4.1 5a.2a 2021-10-16 MDCK3/MDCK3 80 1280 1280 1280 1280 1280 640 A/Sydney/5/2021 pooled clones 10-10 5a.2a 2022-10-31 E3/E2 40 640 640 640 640 1280 320 A/Victoria/4897/2022 5a.2a.1 2022-10-02 SIAT2/MDCK2 80 1280 1280 2560 2560 2560 2560 IVR-238 (A/Victoria/4897/2022) 5a.2a.1 2022-10-02 E3/D6/E1 10-6 40 640 640 1280 1280 1280 640 A/Wisconsin/67/2022 5a.2a.1 2022-10-25 MDCK2 40 1280 640 1280 1280 640 1280
TEST VIRUSES A/Bourgogne/01006/2023 5a.2a 2023-01-09 MDCK1/MDCK1 80 2560 1280 2560 2560 2560 1280 A/Champagne_Ardenne/02319/2023 5a.2a 2023-01-23 MDCK1/MDCK1 40 1280 1280 1280 1280 1280 640 A/Romania/545585/2023 5a.2a 2023-01-26 SIAT2/MDCK1 40 2560 1280 2560 2560 2560 1280 A/Franche_Comte/03222/2023 5a.2a 2023-01-30 MDCK1/MDCK1 40 2560 1280 1280 1280 1280 1280 A/Kosovo/457/2023 5a.2a 2023-02-01 SIAT1 80 1280 1280 1280 2560 2560 1280 A/Kosovo/497/2023 5a.2a 2023-02-02 SIAT1 80 2560 1280 2560 2650 2560 1280 A/Kosovo/518/2023 5a.2a 2023-02-02 SIAT1 80 2560 1280 2560 2560 2560 1280 A/Kosovo/503/2023 5a.2a 2023-02-02 SIAT1 40 2560 1280 2560 2560 2560 1280 A/Belgium/S1359/2023 5a.2a 2023-02-03 MDCK1/MDCK1 40 1280 1280 1280 1280 1280 640 A/Kosovo/1297/2023 5a.2a 2023-02-03 SIAT1 40 1280 1280 1280 1280 1280 640 A/Estonia/173318/2023 5a.2a 2023-02-04 MDCK1 40 1280 640 1280 640 1280 640 A/Ile_de_France/03351/2023 5a.2a 2023-02-06 MDCK1/MDCK1 80 2560 2560 2560 2560 2560 1280 A/Dakar/01/2023 5a.2a 2023-02-06 MDCK2/MDCK1 80 2560 2560 2560 2560 2560 1280 A/Romania/546116/2023 5a.2a 2023-02-07 SIAT1/MDCK1 80 1280 1280 2560 2560 2560 640 A/Romania/546205/2023 5a.2a 2023-02-08 SIAT2/MDCK1 40 1280 640 1280 640 1280 320 A/Champagne_Ardenne/03912/2023 5a.2a 2023-02-13 MDCK1/MDCK1 80 2560 1280 2560 2560 2560 1280 A/Romania/546347/2023 5a.2a 2023-02-13 SIAT2/MDCK1 80 2560 2560 2560 2560 2560 1280 A/Lons_le_Saunier/04313/2023 5a.2a 2023-02-15 MDCK1/MDCK1 80 2560 2560 2560 2560 2560 1280 A/Franche_Comte/04389/2023 5a.2a 2023-02-16 MDCK1/MDCK1 40 640 640 1280 640 640 640 A/Ile_de_France/04334/2023 5a.2a 2023-02-16 MDCK1/MDCK1 80 1280 1280 1280 1280 1280 640 A/Romania/546760/2023 5a.2a 2023-02-21 SIAT2/MDCK1 80 2560 2560 2560 2560 2560 1280 A/Belgium/S1395/2023 5a.2a 2023-02-21 SIAT1/SIAT1 40 1280 1280 1280 1280 1280 640 A/Kosovo/929/2023 5a.2a 2023-02-24 SIAT1 40 1280 1280 1280 1280 1280 640 A/Kosovo/948/2023 5a.2a 2023-02-27 SIAT1 40 1280 640 1280 1280 640 640 A/Kosovo/972/2023 5a.2a 2023-02-28 SIAT1 80 2560 1280 2560 2560 2560 1280 A/Kosovo/986/2023 5a.2a 2023-02-28 SIAT1 40 2560 1280 2560 2560 2560 1280 A/Ile_de_France/05587/2023 5a.2a 2023-03-01 MDCK1/MDCK1 40 2560 1280 2560 1280 2560 640 A/Romania/547563/2023 5a.2a 2023-03-03 SIAT2/MDCK1 80 320 320 320 640 640 320 A/Poland/196/2023 5a.2a 2023-03-06 MDCK1 40 640 640 1280 1280 1280 640 A/Bretagne/06091/2023 5a.2a 2023-03-06 MDCK1/MDCK1 <40 640 320 640 640 640 640 A/Champagne_Ardenne/05898/2023 5a.2a 2023-03-06 MDCK1/MDCK1 80 2560 1280 2560 1280 1280 1280 A/Switzerland/43530/2023 5a.2a 2023-03-07 MDCK1 40 1280 1280 1280 2560 2560 1280 A/Kosovo/1144/2023 5a.2a 2023-03-09 SIAT1 40 2560 1280 2560 2560 2560 1280 A/Poland/160/2023 5a.2a 2023-03-14 MDCK1 40 1280 1280 1280 1280 1280 1280 A/Switzerland/10945/2023 5a.2a 2023-03-14 MDCK1 80 2560 2560 2560 2560 2560 1280 A/Kosovo/1221/2023 5a.2a 2023-03-14 SIAT1 40 640 640 1280 640 1280 640 A/Mauritius/P11349/2023 5a.2a 2023-03-15 MDCK1 40 1280 1280 2560 2560 2560 1280 A/Romania/548449/2023 5a.2a 2023-03-15 SIAT1/MDCK1 80 1280 1280 2560 2560 2560 1280 A/Poland/159/2023 5a.2a 2023-03-16 MDCK1 80 1280 1280 2560 2560 2560 1280 A/Poland/110/2023 5a.2a 2023-03-17 MDCK1 <40 640 320 640 640 1280 640 A/Poland/109/2023 5a.2a 2023-03-17 MDCK1 <40 640 320 1280 1280 1280 640 A/Kosovo/1305/2023 5a.2a 2023-03-20 SIAT1 80 2560 1280 2560 2560 2560 1280 A/Switzerland/77757/2023 5a.2a 2023-03-21 MDCK1 40 1280 1280 1280 1280 640 640 A/Alsace/09577/2023 5a.2a 2023-04-03 MDCK1/MDCK1 80 2560 1280 2560 2560 2560 1280 A/Kosovo/1488/2023 5a.2a 2023-04-04 SIAT1 40 1280 640 1280 640 1280 640 A/Mauritius/P37571/2023 5a.2a 2023-05-17 MDCK1 40 1280 1280 2560 2560 2560 1280 A/Belgium/G0121/2023 5a.2a.1 2023-01-16 MDCK1/SIAT1 <40 1280 640 1280 2560 1280 1280 A/Belgium/G0193/2023 5a.2a.1 2023-02-01 MDCK1/MDCK1 40 1280 640 1280 2560 1280 1280 A/Nord_Pas_de_Calais/02690/2023 no seq 2023-01-30 MDCK1/MDCK1 40 2560 1280 2560 2560 2560 1280 A/Belgium/S1376/2023 no seq 2023-02-07 MDCK1/MDCK1 80 2560 1280 2560 2560 2560 1280 A/Belgium/G0200/2023 no seq 2023-02-08 MDCK1/MDCK1 <40 1280 640 640 1280 1280 640 A/Ile_de_France/05015/2023 no seq 2023-02-27 MDCK1/MDCK1 40 1280 1280 2560 1280 1280 640 A/Ile_de_France/05470/2023 no seq 2023-03-01 MDCK1/MDCK1 40 2560 1280 2560 2560 2560 640
Vaccine Vaccine Vaccine < relates to the lowest dilution of antiserum used NH 2020-21 SH 2021 NH 2023-24 ND = Not Done NH 2021-22
SH 2022 NH 2022-23
Vaccine SH 2023
15
HI Tables: H3
Table H3-11. Antigenic analyses of influenza A(H3N2) viruses (Guinea Pig RBC with 20nM Oseltamivir) 2023-05-26
Viruses Collection Passage A/Camb A/Camb A/Thuringen A/Stockholm A/Darwin A/Norway A/Norway A/Poland A/Slovenia A/Lille A/Catal date history 925256/20 e0826360/20 10/22 5/21 9/21 24873/21 24873/21 97/22 8720/22 50053/22 NSVH-2067/22
Passage history SIAT Egg SIAT SIAT Egg SIAT Egg SIAT SIAT SIAT SIAT Ferret number F03/21 F10/21 F36/22 F15/22 F39/21 F10/22 F11/22 F39/22 F24/22 F02/23 F41/22 Genetic group 1a 1a 2b 2a 2a 2a.3 2a.3 2a.2 2a.1 2a.1 2a.1b
REFERENCE VIRUSES A/Cambodia/925256/2020 1a 2020-09-25 SIAT5 640 320 40 160 320 80 80 160 <40 160 40 A/Cambodia/e0826360/2020 1a 2020-07-16 E5/E2 160 1280 80 160 320 80 80 40 160 320 40 A/Thuringen/10/2022 2b 2022-04-01 P1/SIAT2 160 320 640 640 640 160 320 160 640 640 160 A/Stockholm/5/2021 2a 2021-04-16 SIAT0/SIAT4 160 160 160 640 1280 160 320 640 1280 640 320 A/Darwin/9/2021 2a 2021-04-17 E3/E2 80 640 160 640 640 160 320 320 640 640 160 A/Norway/24873/2021 2a.3 2021-10-24 SIAT3 160 160 160 320 320 160 320 160 640 320 320 A/Norway/24873/2021 2a.3 2021-10-24 E3/E1 160 320 320 640 640 640 640 320 640 640 320 A/Poland/97/2022 2a.2 2022-05-09 SIAT3 80 160 160 640 640 160 320 1280 640 1280 640 A/Slovenia/8720/2022 2a.1 2022-02-10 SIAT1/MDCK1/SIAT2 160 160 160 640 1280 320 640 640 1280 1280 1280 A/Lille/50053/2022 2a.1 2022-09-06 MDCK1/SIAT5 80 160 80 320 640 80 160 320 640 2560 320 A/Catalonia/NSVH161512067/2022 2a.1b 2022-09-14 SIAT1/SIAT3 80 80 160 320 640 160 160 640 1280 1280 640 TEST VIRUSES A/Georgia/T18-45/2022 2a.1b 2022-11-28 SIAT1 80 80 160 160 320 80 160 320 640 640 320 A/Georgia/T26-26/2022 2a.1b 2022-12-05 SIAT1 80 160 80 160 320 80 160 320 640 2560 640 A/Estonia/172437/2022 2a.1b 2022-12-14 SIAT1 40 80 80 160 320 80 160 160 640 640 320 A/Estonia/172464/2022 2a.1b 2022-12-19 SIAT1 80 160 80 160 320 80 160 320 640 1280 640 A/Estonia/KL7277/2022 2a.1b 2022-12-28 SIAT1 80 160 80 320 320 80 160 320 640 1280 640 A/Estonia/172631/2023 2a.1b 2023-01-01 SIAT1 80 80 160 320 320 80 160 320 640 640 320 A/Slovenia/125/2023 2a.1b 2023-01-09 MDCK0/SIAT1 80 80 160 160 640 80 160 320 640 640 320 A/Slovenia/110/2023 2a.1b 2023-01-09 SIAT0/SIAT1 80 80 160 320 640 80 160 320 640 1280 640 A/Estonia/172886/2023 2a.1b 2023-01-11 SIAT1 40 80 160 320 640 80 160 320 1280 1280 640 A/Slovenia/158/2023 2a.1b 2023-01-11 MDCK0/SIAT1 80 160 160 320 640 160 160 320 640 640 320 A/Serbia/263/2023 2a.1b 2023-01-12 SIAT1 80 160 160 320 640 160 320 640 1280 1280 640 A/Estonia/172883/2023 2a.1b 2023-01-13 SIAT1 80 160 160 320 640 160 320 640 640 1280 640 A/Slovenia/277/2023 2a.1b 2023-01-20 MDCK0/SIAT1 80 80 160 320 640 80 160 320 640 640 320 A/Estonia/173486/2023 2a.1b 2023-02-19 SIAT1 40 80 80 320 320 80 160 320 640 320 320 A/Estonia/173578/2023 2a.1b 2023-02-25 SIAT1 40 80 80 160 320 80 160 160 320 320 160 A/Slovenia/657/2023 2a.1b 2023-03-01 MDCKf0/SIAT1 80 80 160 320 640 80 160 320 640 640 320 A/Estonia/173645/2023 2a.1b 2023-03-02 SIAT1 40 160 160 320 640 160 320 320 640 640 320 A/Estonia/173616/2023 2a.1b 2023-03-06 SIAT1 40 80 80 320 320 80 160 320 320 320 160 A/Estonia/173741/2023 2a.1b 2023-03-08 SIAT1 40 80 160 160 320 80 160 320 320 320 160 A/Togo/2082/2022 2a.3a 2022-10-06 SIAT1 80 320 320 640 640 320 640 320 640 640 160 A/Ireland/80522/2022 2a.3a.1 2022-12-22 SIAT3 40 160 160 160 320 160 640 160 320 320 160 A/Serbia/500898/2023 2a.3a.1 2023-01-06 SIAT1 40 160 160 320 640 320 640 160 320 320 160 A/Bulgaria/246/2023 2a.3a.1 2023-01-15 SIAT2/SIAT1 80 320 320 320 640 320 640 320 640 640 160 A/Serbia/7028/2022 2b 2022-12-23 SIAT1 80 160 320 320 320 80 160 80 320 160 80 A/Estonia/172575/2022 2b 2022-12-24 SIAT1 160 320 640 320 320 160 160 160 320 320 80 A/Ireland/81103/2022 2b 2022-12-25 SIAT3 80 160 320 320 320 80 160 160 320 320 80 A/Serbia/3/2023 2b 2023-01-02 SIAT1 80 160 320 320 320 80 80 80 160 640 40 A/Macedonia/133/2023 2b 2023-01-09 SIAT1 80 160 320 320 320 80 160 80 320 320 80 A/Macedonia/213/2023 2b 2023-01-11 SIAT1 80 160 320 320 320 80 80 160 320 640 80 A/Serbia/501681/2023 2b 2023-01-12 SIAT1 80 320 320 320 320 80 160 160 320 640 80 A/Bulgaria/632/2023 2b 2023-01-16 SIAT2/SIAT1 160 320 640 640 640 320 320 160 640 640 160 A/Bulgaria/627/2023 2b 2023-01-16 SIAT2/SIAT1 80 320 320 320 320 160 160 160 320 1280 80 A/Bulgaria/625/2023 2b 2023-01-16 SIAT2/SIAT1 80 160 320 320 320 80 80 80 160 640 40 A/Bulgaria/508/2023 2b 2023-01-16 SIAT2/SIAT1 160 320 640 320 640 160 320 160 320 320 80 A/Estonia/173033/2023 2b 2023-01-17 SIAT1 80 160 320 320 320 160 160 160 320 320 80 A/Estonia/173028/2023 2b 2023-01-21 SIAT1 160 320 640 320 640 160 320 160 640 320 80 A/Estonia/173038/2023 2b 2023-01-23 SIAT1 160 320 320 320 320 160 160 160 320 320 80 A/Estonia/173097/2023 2b 2023-01-23 SIAT1 80 160 320 320 320 80 160 80 320 160 80 A/Estonia/173253/2023 2b 2023-02-02 SIAT1 80 160 320 320 320 160 160 80 320 320 80 A/Bulgaria/1427/2023 2b 2023-02-09 SIAT2/SIAT2 80 160 320 320 320 160 160 160 320 640 40 A/Estonia/KL283/2023 2b 2023-02-15 SIAT1 80 160 320 320 320 80 160 80 320 160 80 A/Slovenia/526/2023 2b 2023-02-17 SIAT0/SIAT2 80 160 320 320 320 80 80 80 320 640 40
< relates to the lowest dilution of antiserum used Vaccine Vaccine ND = Not Done NH 2021-22 SH 2022
NH 2022-23 SH 2023
NH 2023-24
Haemagglutination inhibition titre Post-infection ferret antisera
16
Table H3-12. Antigenic analyses of influenza A(H3N2) viruses (Guinea Pig RBC with 20nM Oseltamivir) 2023-06-09
Viruses Collection Passage A/Camb A/Camb A/Thuringen A/Stockholm A/Darwin A/Norway A/Norway A/Poland A/Slovenia A/Lille A/Catal date history 925256/20 e0826360/20 10/22 5/21 9/21 24873/21 24873/21 97/22 8720/22 50053/22 NSVH-2067/22
Passage history SIAT Egg SIAT SIAT Egg SIAT Egg SIAT SIAT SIAT SIAT Ferret number F03/21 F10/21 F36/22 F15/22 F39/21 F10/22 F11/22 F39/22 F24/22 F02/23 F41/22 Genetic group 1a 1a 2b 2a 2a 2a.3 2a.3 2a.2 2a.1 2a.1 2a.1b
REFERENCE VIRUSES A/Cambodia/925256/2020 1a 2020-09-25 SIAT5 640 320 80 160 320 80 160 160 40 160 40 A/Cambodia/e0826360/2020 1a 2020-07-16 E5/E2 160 1280 80 160 320 80 80 80 320 320 <40 A/Thuringen/10/2022 2b 2022-04-01 P1/SIAT2 80 320 320 320 320 160 320 160 320 320 160 A/Stockholm/5/2021 2a 2021-04-16 SIAT0/SIAT4 160 160 160 640 640 80 320 320 640 320 320 A/Darwin/9/2021 2a 2021-04-17 E3/E2 80 640 160 640 1280 160 320 320 640 640 160 A/Norway/24873/2021 2a.3 2021-10-24 SIAT4 80 160 160 320 640 320 640 160 320 320 320 A/Norway/24873/2021 2a.3 2021-10-24 E3/E1 80 320 320 320 640 320 640 320 640 640 320 A/Poland/97/2022 2a.2 2022-05-09 SIAT3 80 160 80 640 640 160 320 640 640 640 320 A/Slovenia/8720/2022 2a.1 2022-02-10 SIAT1/MDCK1/SIAT2 160 160 160 640 640 160 640 640 1280 1280 640 A/Lille/50053/2022 2a.1 2022-09-06 MDCK1/SIAT5 80 160 80 320 320 80 160 320 640 2560 640 A/Catalonia/NSVH161512067/2022 2a.1b 2022-09-14 SIAT1/SIAT3 40 80 80 320 640 80 160 320 1280 640 640 TEST VIRUSES A/SaudiArabia/1404/2022 2a 2022-10-05 SIAT1 80 80 160 320 640 80 160 320 320 320 160 A/Catalonia/3505472NS/2022 2a.1b 2022-09-25 SIAT1 40 80 160 320 320 80 160 320 640 640 640 A/Greece/370/2022 2a.1b 2022-11-07 SIAT1 40 80 160 160 320 80 160 320 640 640 320 A/Catalonia/2262797NS/2022 2a.1b 2022-12-01 SIAT1 80 160 160 320 640 80 160 320 640 1280 640 A/Netherlands/12136/2022 2a.1b 2022-12-29 MDCK-MIX2/SIAT1 40 80 160 320 320 80 160 320 640 640 640 A/Estonia/172629/2023 2a.1b 2023-01-02 SIAT2 40 40 80 160 320 80 160 320 640 640 320 A/Greece/ILI_236/2023 2a.1b 2023-01-02 SIAT1 40 80 80 160 320 80 80 320 320 640 320 A/Greece/ILI_237/2023 2a.1b 2023-01-03 SIAT1 40 80 80 160 320 80 160 320 640 640 320 A/Greece/15/2023 2a.1b 2023-01-09 SIAT1 40 40 80 160 320 80 80 320 640 640 320 A/Armenia/167/2023 2a.1b 2023-01-11 SIAT1 40 80 80 320 320 80 160 320 640 640 640 A/Netherlands/10142/2023 2a.1b 2023-01-12 MDCK-MIX2/SIAT1 80 160 320 640 1280 160 320 1280 1280 1280 640 A/Netherlands/10226/2023 2a.1b 2023-01-29 MDCK-MIX2/SIAT1 40 80 160 160 320 160 80 320 640 640 640 A/Netherlands/10228/2023 2a.1b 2023-01-30 MDCK-MIX2/SIAT1 80 160 160 320 640 80 160 640 1280 1280 640 A/Ireland/9047/2023 2a.1b 2023-02-04 SIAT1 40 80 80 160 160 80 80 160 640 640 160 A/Ireland/9830/2023 2a.1b 2023-02-08 SIAT1 40 80 160 320 640 80 160 320 320 320 160 A/Netherlands/10277/2023 2a.1b 2023-02-09 MDCK-MIX2/SIAT1 80 320 160 320 640 80 160 320 1280 1280 640 A/Ireland/21983/2023 2a.1b 2023-04-02 SIAT1 40 80 80 160 160 80 80 160 320 320 160 A/Greece/267/2022 2a.3a.1 2022-10-17 SIAT1 40 80 160 160 320 160 320 80 160 320 160 A/Blida/42154/2022 2a.3a.1 2022-11-07 SIAT2 80 160 160 160 320 320 640 160 320 320 160 A/SaudiArabia/2439/2022 2a.3a.1 2022-11-14 SIAT1 40 80 160 80 160 160 320 80 80 160 80 A/Boumerdes/44092/2022 2a.3a.1 2022-12-07 SIAT1 <40 40 80 80 160 160 320 80 160 80 40 A/Netherlands/11905/2022 2a.3a.1 2022-12-13 MDCK-MIX2/SIAT1 40 40 160 160 320 320 640 320 320 160 160 A/Catalonia/3512677NS/2022 2a.3a.1 2022-12-19 SIAT1 40 80 160 160 320 320 320 160 160 160 80 A/Bouira/44511/2022 2a.3a.1 2022-12-20 SIAT1 80 80 160 160 320 320 640 160 160 320 160 A/Netherlands/10160/2023 2a.3a.1 2023-01-22 MDCK-MIX2/SIAT1 80 160 320 320 640 640 640 320 320 320 320 A/Netherlands/10132/2023 2a.3b 2023-01-16 MDCK-MIX2/SIAT1 40 80 160 320 640 80 160 320 640 1280 640 A/SaudiArabia/556/2022 2b 2022-06-25 SIAT1 80 80 320 160 160 40 80 80 160 160 40 A/Catalonia/2232752NS/2022 2b 2022-10-07 SIAT1 80 160 320 320 320 80 160 160 160 320 40 A/Catalonia/3506449NS/2022 2b 2022-10-10 SIAT1 40 80 320 160 160 40 80 80 160 160 40 A/Greece/386/2022 2b 2022-11-07 SIAT1 40 80 160 160 160 80 80 80 160 320 40 A/Greece/416/2022 2b 2022-11-16 SIAT1 80 160 160 320 160 40 80 80 160 320 40 A/Greece/415/2022 2b 2022-11-16 SIAT1 80 160 160 320 160 80 80 80 160 320 40 A/Catalonia/3514090NS/2022 2b 2022-12-30 SIAT1 160 160 320 320 320 80 160 160 320 320 80 A/Greece/ILI_113/2023 2b 2023-01-02 SIAT1 80 160 320 320 320 80 160 80 320 320 80 A/Greece/ILI_196/2023 2b 2023-01-03 SIAT1 80 160 320 320 160 80 80 80 160 640 40 A/Greece/ILI_249/2023 2b 2023-01-04 SIAT1 80 320 320 320 320 80 80 80 640 160 40 A/Greece/ILI_433/2023 2b 2023-01-10 SIAT1 80 80 320 320 160 80 160 80 160 160 80 A/Netherlands/10162/2023 2b 2023-01-23 MDCK-MIX2/SIAT1 80 320 320 320 320 80 160 160 320 640 40 A/Ireland/8169/2023 2b 2023-02-01 SIAT1 40 80 320 160 160 80 80 80 160 160 40 A/Netherlands/10192/2023 2b 2023-02-01 MDCK-MIX2/SIAT1 80 160 320 320 320 80 160 160 320 320 80 A/Ireland/9468/2023 2b 2023-02-07 SIAT2 80 160 320 320 320 80 160 160 320 320 80 A/Netherlands/10290/2023 2b 2023-02-14 MDCK-MIX2/SIAT1 160 320 640 640 320 160 160 160 320 320 80 A/Ireland/8661/2023 no seq 2023-02-02 SIAT2 80 160 320 320 160 80 160 80 320 160 40 A/Ireland/9045/2023 no seq 2023-02-04 SIAT1 40 80 160 320 320 80 160 320 1280 1280 640
< relates to the lowest dilution of antiserum used Vaccine Vaccine ND = Not Done NH 2021-22 SH 2022
NH 2022-23 SH 2023
NH 2023-24
Haemagglutination inhibition titre Post-infection ferret antisera
17
HI tables: Influenza B
Table BV-9. Antigenic analyses of influenza B viruses (Victoria lineage) 2023-05-24
Viruses Other Collection Passage B/Bris B/Colorado B/Wash'ton B/Neth B/Neth B/Austria B/Austria B/Austria B/Stock information date history 60/08 06/17 02/19 11267/22 10894/22 1359417/21 1359417/21 1359417/21 3/22
Passage history Egg Egg Egg MDCK Egg MDCK Egg G141 Egg G141R MDCK
Ferret number
Sh 539, 540, 543, 544, 570, 571, 5741
F44/18 F20/20 F29/22 F37/22 NIB F01/21 F15/21 F44/21 F28/22
Genetic group V1A V1A.1 V1A.3 V1A.3 V1A.3 V1A.3a.2 V1A.3a.2 V1A.3a.2 V1A.3a.2
REFERENCE VIRUSES B/Brisbane/60/2008 V1A 2008-08-04 E4/E4 1280 160 40 <10 40 <40 <40 <40 <40 B/Colorado/06/2017 V1A.1 2017-02-05 E5/E2 1280 640 80 10 80 <40 <40 <40 <40 B/Washington/02/2019 V1A.3 2019-01-19 E3/E3 640 160 160 20 80 <40 <40 <40 <40 B/Netherlands/11267/2022 V1A.3 2022-04-14 MDCK-MIX/MDCK2 <40 <10 <10 80 20 <40 <40 <40 <40 B/Netherlands/10894/2022 V1A.3 2022-04-02 E4/E1 640 40 40 40 80 <40 <40 <40 <40 B/Austria/1359417/2021 G141 V1A.3a.2 2021-01-09 SIAT1/MDCK4 320 <10 <10 10 <10 640 640 160 320 B/Austria/1359417/2021 Isolate 2 G141 V1A.3a.2 2021-01-09 E3/E4 320 <10 <10 40 10 1280 640 320 320 B/Austria/1359417/2021 Isolate 2 G141R V1A.3a.2 2021-01-09 E3/E5 160 <10 <10 20 <10 640 640 2560 320 B/Stockholm/3/2022 V1A.3a.2 2022-03-22 SIAT1/MDCK3 320 <10 <10 20 <10 640 640 320 640 TEST VIRUSES B/Slovenia/186/2023 V1A.3a.2 2023-01-16 MDCK0/MDCK1 320 <10 <10 <10 <10 640 640 160 640 B/Slovenia/237/2023 V1A.3a.2 2023-01-19 MDCK0/MDCK1 320 <10 <10 <10 <10 640 640 160 640 B/Newport/4988/2023 V1A.3a.2 2023-01-20 MDCK2 640 <10 <10 10 <10 640 640 320 640 B/Slovenia/265/2023 V1A.3a.2 2023-01-23 MDCK0/MDCK1 320 <10 <10 <10 <10 640 640 320 640 B/Slovenia/293/2023 V1A.3a.2 2023-01-24 MDCK0/MDCK1 640 <10 <10 <10 <10 640 640 320 640 B/Slovenia/304/2023 V1A.3a.2 2023-01-25 MDCK0/MDCK1 320 <10 <10 <10 <10 640 640 160 640 B/Slovenia/359/2023 V1A.3a.2 2023-01-31 MDCK0/MDCK1 320 <10 <10 <10 <10 640 640 320 640 B/Slovenia/404/2023 V1A.3a.2 2023-02-05 MDCK0/MDCK1 320 <10 <10 <10 <10 640 320 160 640 B/Slovenia/414/2023 V1A.3a.2 2023-02-06 MDCK0/MDCK1 320 <10 <10 <10 <10 1280 640 320 640 B/Slovenia/500/2023 V1A.3a.2 2023-02-15 SIAT0/MDCK1 640 <10 <10 <10 <10 640 640 320 640 B/Slovenia/505/2023 V1A.3a.2 2023-02-16 SIAT0/MDCK1 320 <10 <10 <10 <10 640 320 160 320 B/Slovenia/547/2023 V1A.3a.2 2023-02-20 MDCK0/MDCK1 320 <10 <10 <10 <10 640 640 320 640 B/Slovenia/590/2023 V1A.3a.2 2023-02-22 MDCK0/MDCK1 640 <10 <10 <10 <10 640 640 320 640 B/Slovenia/635/2023 V1A.3a.2 2023-02-27 MDCK0/MDCK1 320 <10 <10 <10 <10 640 640 320 640 B/Slovenia/621/2023 V1A.3a.2 2023-02-27 MDCK0/MDCK1 320 <10 <10 <10 <10 320 640 160 640 B/Slovenia/665/2023 V1A.3a.2 2023-02-28 MDCKf0/MDCK1 320 <10 <10 <10 <10 640 640 320 640 B/Slovenia/698/2023 V1A.3a.2 2023-03-05 SIAT0/MDCK1 320 <10 <10 <10 <10 640 640 320 640 B/Slovenia/724/2023 V1A.3a.2 2023-03-06 MDCK0/MDCK1 640 <10 <10 <10 <10 640 1280 320 640 B/Slovenia/732/2023 V1A.3a.2 2023-03-06 MDCK0/MDCK1 320 <10 <10 <10 <10 640 640 320 640 B/Slovenia/726/2023 V1A.3a.2 2023-03-06 MDCK0/MDCK1 320 <10 <10 <10 <10 320 640 160 320 B/Slovenia/744/2023 V1A.3a.2 2023-03-07 MDCK0/MDCK1 320 <10 <10 <10 <10 640 640 320 640 B/Slovenia/778/2023 V1A.3a.2 2023-03-08 MDCKf0/MDCK1 640 <10 <10 <10 <10 640 640 320 640 B/Slovenia/758/2023 V1A.3a.2 2023-03-08 MDCKf0/MDCK1 320 <10 <10 <10 <10 1280 640 320 640 B/Slovenia/743/2023 V1A.3a.2 2023-03-08 MDCK0/MDCK1 320 <10 <10 <10 <10 640 640 320 640 B/Slovenia/853/2023 V1A.3a.2 2023-03-14 MDCKf0/MDCK1 640 <10 <10 20 <10 640 640 320 640 B/Slovenia/824/2023 V1A.3a.2 2023-03-14 MDCKf0/MDCK1 640 <10 <10 <10 <10 640 640 320 640 B/Slovenia/924/2023 V1A.3a.2 2023-03-22 MDCKf0/MDCK1 640 <10 <10 <10 <10 640 640 320 640 B/Slovenia/938/2023 V1A.3a.2 2023-03-23 MDCK0/MDCK1 640 <10 <10 <10 <10 640 640 160 640 B/Slovenia/979/2023 V1A.3a.2 2023-03-28 MDCK0/MDCK1 320 <10 <10 10 <10 640 640 160 640 B/Slovenia/1035/2023 V1A.3a.2 2023-04-06 MDCKf0/MDCK1 320 <10 <10 <10 <10 640 640 320 640 B/Slovenia/1052/2023 V1A.3a.2 2023-04-07 MDCKf0/MDCK1 640 <10 <10 <10 <10 640 640 320 640 B/Estonia/174172/2023 V1A.3a.2 2023-04-11 MDCK1 320 <10 <10 <10 <10 1280 640 320 320 B/Estonia/174175/2023 V1A.3a.2 2023-04-12 MDCK1 320 <10 <10 <10 <10 640 640 320 640 B/Estonia/KL549/2023 V1A.3a.2 2023-04-13 MDCK1 320 <10 <10 <10 <10 640 640 160 640 B/Estonia/KL548/2023 V1A.3a.2 2023-04-13 MDCK1 320 <10 <10 <10 <10 640 640 320 640 B/Estonia/174174/2023 V1A.3a.2 2023-04-14 MDCK1 320 <10 <10 <10 <10 640 320 160 320
Vaccine NH 2021-22
NH 2022-23 SH 2023
NH 2023-24
Haemagglutination inhibition titre Post-infection ferret antiserum
< relates to the lowest dilution of antiserum used Vaccine 1 hyperimmune sheep serum; ND = Not Done SH 2022
18
Table BV-10. Antigenic analyses of influenza B viruses (Victoria lineage) 2023-06-01
Viruses Other Collection Passage B/Bris B/Colorado B/Wash'ton B/Neth B/Neth B/Austria B/Austria B/Austria B/Stock information date history 60/08 06/17 02/19 11267/22 10894/22 1359417/21 1359417/21 1359417/21 3/22
Passage history Egg Egg Egg MDCK Egg MDCK Egg G141 Egg G141R MDCK
Ferret number
Sh 539, 540, 543, 544, 570, 571, 5741
F44/18 F20/20 F29/22 F37/22 NIB F01/21 F15/21 F44/21 F28/22
Genetic group V1A V1A.1 V1A.3 V1A.3 V1A.3 V1A.3a.2 V1A.3a.2 V1A.3a.2 V1A.3a.2
REFERENCE VIRUSES B/Brisbane/60/2008 V1A 2008-08-04 E4/E4 1280 80 40 <10 80 <40 <40 <40 <40 B/Colorado/06/2017 V1A.1 2017-02-05 E5/E2 640 320 80 <10 160 <40 <40 <40 <40 B/Washington/02/2019 V1A.3 2019-01-19 E3/E3 320 80 160 20 160 <40 <40 <40 <40 B/Netherlands/11267/2022 V1A.3 2022-04-14 MDCK-MIX/MDCK2 <40 <10 <10 80 40 <40 <40 <40 <40 B/Netherlands/10894/2022 V1A.3 2022-04-02 E4/E1 320 20 40 40 160 <40 <40 <40 <40 B/Austria/1359417/2021 G141 V1A.3a.2 2021-01-09 SIAT1/MDCK4 160 <10 <10 10 <10 640 640 160 320 B/Austria/1359417/2021 Isolate 2 G141 V1A.3a.2 2021-01-09 E3/E4 320 <10 10 20 10 1280 640 320 640 B/Austria/1359417/2021 Isolate 2 G141R V1A.3a.2 2021-01-09 E3/E5 160 <10 <10 20 <10 1280 640 2560 320 B/Stockholm/3/2022 V1A.3a.2 2022-03-22 SIAT1/MDCK3 320 <10 <10 10 <10 640 640 320 640 TEST VIRUSES B/Astana/18844/2022 (11902) V1A.3 MDCK1 1280 20 80 40 80 40 <40 <40 <40 B/Bosnia and Herzegovina/48/2022 V1A.3a.2 2022-11-22 MDCK1 640 20 <10 20 <10 640 640 320 640 B/Estonia/172050/2022 V1A.3a.2 2022-12-01 MDCK1 320 <10 <10 10 <10 1280 640 320 320 B/Estonia/172315/2022 V1A.3a.2 2022-12-05 MDCK1 320 10 10 10 <10 640 640 160 640 B/Bosnia and Herzegovina/61/2022 V1A.3a.2 2022-12-06 MDCK1 640 20 10 20 <10 640 640 320 640 B/Serbia/499177/2022 V1A.3a.2 2022-12-15 MDCK1 640 <10 10 20 <10 1280 640 320 1280 B/Serbia/500612/2023 V1A.3a.2 2023-01-04 MDCK1 640 <10 10 20 <10 640 640 320 640 B/Serbia/354/2023 V1A.3a.2 2023-01-15 MDCK1 320 <10 10 20 <10 1280 640 320 640 B/Macedonia/335/2023 V1A.3a.2 2023-01-17 MDCK1 320 10 10 20 <10 640 640 320 640 B/Estonia/173044/2023 V1A.3a.2 2023-01-20 MDCK1 320 10 <10 20 <10 1280 640 320 640 B/Bulgaria/1485/2023 V1A.3a.2 2023-02-14 MDCK2/MDCK1 640 20 10 20 <10 640 640 320 640 B/Bulgaria/1643/2023 V1A.3a.2 2023-02-22 MDCK2/MDCK1 640 20 10 10 <10 640 640 160 640 B/Bulgaria/1646/2023 V1A.3a.2 2023-02-23 MDCK2/MDCK1 320 <10 <10 10 <10 1280 640 320 320 B/Bulgaria/1671/2023 V1A.3a.2 2023-03-07 MDCK2/MDCK1 640 20 10 10 <10 640 640 320 640 B/Bulgaria/1734/2023 V1A.3a.2 2023-03-14 MDCK2/MDCK1 320 10 <10 10 <10 640 640 160 640 B/Bulgaria/1757/2023 V1A.3a.2 2023-03-15 MDCK2/MDCK1 640 20 10 20 <10 640 640 320 640 B/Bulgaria/1756/2023 V1A.3a.2 2023-03-15 MDCK2/MDCK1 320 <10 <10 20 <10 1280 640 320 320 B/Bulgaria/1860/2023 V1A.3a.2 2023-03-21 MDCK2/MDCK1 320 10 <10 20 <10 1280 640 320 320 B/Bulgaria/1830/2023 V1A.3a.2 2023-03-21 MDCK2/MDCK1 320 10 10 20 <10 640 640 320 640 B/Bulgaria/1826/2023 V1A.3a.2 2023-03-21 MDCK2/MDCK1 320 10 10 20 <10 640 640 320 640 B/Bulgaria/1823/2023 V1A.3a.2 2023-03-21 MDCK2/MDCK1 320 10 10 20 <10 640 640 320 640 B/Bulgaria/1808/2023 V1A.3a.2 2023-03-21 MDCK2/MDCK1 320 10 10 20 <10 640 640 320 640 B/Bulgaria/1903/2023 D197N (+CHO) V1A.3a.2 2023-03-27 MDCK2/MDCK1 <40 <10 <10 20 <10 40 <40 <40 <40 B/Bulgaria/1896/2023 D197N (+CHO) V1A.3a.2 2023-03-27 MDCK2/MDCK1 <40 <10 <10 20 <10 40 <40 <40 <40 B/Bulgaria/1915/2023 V1A.3a.2 2023-03-29 MDCK2/MDCK1 640 20 <10 20 <10 640 640 320 640 B/Bulgaria/1929/2023 V1A.3a.2 2023-04-04 MDCK2/MDCK1 320 <10 <10 10 <10 1280 640 320 320 B/Slovenia/1024/2023 V1A.3a.2 2023-04-05 MDCKf0/MDCK3 320 10 <10 20 <10 640 640 320 640 B/EastKazakhstan/1015/2022 (11954) V1A.3a.2 MDCK1 640 <10 10 20 <10 1280 1280 320 1280
Vaccine NH 2021-22
NH 2022-23 SH 2023
NH 2023-24
Haemagglutination inhibition titre Post-infection ferret antiserum
< relates to the lowest dilution of antiserum used Vaccine 1 hyperimmune sheep serum; ND = Not Done SH 2022
19
Table BV-14. Antigenic analyses of influenza B viruses (Victoria lineage) 2023-07-25
Viruses Other Collection Passage B/Bris B/Wash'ton B/Austria B/Austria B/Austria B/Stock information date history 60/08 02/19 1359417/21 1359417/21 1359417/21 3/22
Passage history Egg Egg MDCK Egg G141 Egg G141R MDCK
Ferret number Sh 539,
540, 543, 544, 570, 571, 5741
F20/20 NIB F01/21 F15/21 F44/21 F28/22
Genetic group V1A V1A.3 V1A.3a.2 V1A.3a.2 V1A.3a.2 V1A.3a.2
REFERENCE VIRUSES B/Brisbane/60/2008 V1A 2008-08-04 E4/E4 1280 80 <40 <40 <40 <40 B/Washington/02/2019 V1A.3 2019-01-19 E3/E3 640 320 <40 <40 <40 <40 B/Austria/1359417/2021 V1A.3a.2 2021-01-09 SIAT1/MDCK4 160 <10 640 640 320 320 B/Austria/1359417/2021 Isolate 2 V1A.3a.2 2021-01-09 E3/E4 160 <10 640 640 160 320 B/Austria/1359417/2021 Isolate 2 V1A.3a.2 2021-01-09 E3/E5 160 <10 1280 320 2560 320 B/Stockholm/3/2022 V1A.3a.2 2022-03-22 SIAT1/MDCK3 320 <10 640 320 320 640 TEST VIRUSES B/Medea/43411/2022 V1A.3a.2 2022-11-23 MDCK1 320 <10 1280 640 320 320 B/Tebessa/43789/2022 V1A.3a.2 2022-12-01 MDCK1 320 <10 1280 320 320 320 B/Uppsala/1/2023 V1A.3a.2 2023-01-02 SIAT1/MDCK1 320 <10 640 320 320 320 B/South Africa/R00198/23 V1A.3a.2 2023-01-09 MDCK1/MDCK1 320 <10 1280 320 320 320 B/BosniaAndHerzegovina/148/2023 V1A.3a.2 2023-01-24 MDCK2 320 <10 1280 320 320 320 B/Parma/9/2023 V1A.3a.2 2023-02-01 MDCK3/MDCK1 320 <10 640 320 160 640 B/Parma/10/2023 V1A.3a.2 2023-02-03 MDCK3/MDCK1 320 <10 640 320 160 320 B/Perugia/4/2023 V1A.3a.2 2023-02-03 MDCK3/MDCK1 160 <10 320 320 160 320 B/Armenia/600/2023 V1A.3a.2 2023-02-06 MDCK2 320 <10 1280 320 320 320 B/Ireland/9152/2023 V1A.3a.2 2023-02-06 MDCK1 320 <10 640 320 160 640 B/Switzerland/58634/2023 V1A.3a.2 2023-02-06 MDCK1/MDCK1 640 <10 640 320 320 640 B/Switzerland/45344/2023 V1A.3a.2 2023-02-06 MDCK1/MDCK1 320 <10 320 160 160 320 B/Hungary/40/2023 V1A.3a.2 2023-02-06 MDCK1/MDCK1 160 <10 640 320 160 320 B/Serbia/1124/2023 V1A.3a.2 2023-02-06 C1/MDCK1 320 <10 640 320 160 640 B/Parma/7/2023 V1A.3a.2 2023-02-06 MDCK3/MDCK1 320 <10 1280 320 320 320 B/Armenia/622/2023 V1A.3a.2 2023-02-07 MDCK1 640 <10 640 320 160 640 B/Ireland/9627/2023 V1A.3a.2 2023-02-08 MDCK1 320 <10 640 320 160 320 B/Switzerland/6471/2023 V1A.3a.2 2023-02-10 MDCK1/MDCK1 320 <10 640 320 160 320 B/Parma/11/2023 V1A.3a.2 2023-02-13 MDCK3/MDCK1 320 10 640 320 320 320 B/Switzerland/51774/2023 V1A.3a.2 2023-02-14 MDCK1/MDCK1 320 <10 1280 320 320 320 B/Hungary/46/2023 V1A.3a.2 2023-02-14 MDCK1/MDCK1 320 <10 640 320 320 320 B/Hungary/64/2023 V1A.3a.2 2023-02-14 MDCK1/MDCK1 320 <10 640 320 160 320 B/Serbia/1430/2023 V1A.3a.2 2023-02-14 C2/MDCK1 320 10 640 320 160 640 B/Serbia/1428/2023 V1A.3a.2 2023-02-14 C1/MDCK1 320 10 640 320 160 640 B/Serbia/1415/2023 V1A.3a.2 2023-02-14 C1/MDCK1 320 <10 640 320 160 640 B/Parma/16/2023 V1A.3a.2 2023-02-14 MDCK3/MDCK1 320 10 640 320 160 640 B/Parma/15/2023 V1A.3a.2 2023-02-14 MDCK3/MDCK1 640 10 640 320 160 320 B/Ireland/13684/2023 V1A.3a.2 2023-02-16 MDCK1 320 <10 640 320 160 640 B/Stockholm/6/2023 V1A.3a.2 2023-02-16 SIAT1/MDCK1 320 <10 640 320 160 640 B/Orebro/1/2023 V1A.3a.2 2023-02-19 SIAT1/MDCK1 320 <10 640 320 320 640 B/Stockholm/2/2023 V1A.3a.2 2023-02-20 SIAT1/MDCK1 320 <10 640 320 160 640 B/Norway/3749/2023 V1A.3a.2 2023-02-22 MDCK1 320 <10 640 320 160 320 B/Norway/3226/2023 V1A.3a.2 2023-02-22 MDCK1 320 <10 1280 320 320 320 B/Hungary/75/2023 V1A.3a.2 2023-02-24 MDCK1/MDCK1 320 <10 640 320 160 640 B/Karlstad/1/2023 V1A.3a.2 2023-02-25 SIAT1/MDCK1 320 <10 640 320 160 640 B/Switzerland/64703/2023 V1A.3a.2 2023-02-27 MDCK1/MDCK1 320 <10 640 320 320 640 B/Serbia/2225/2023 V1A.3a.2 2023-02-28 C1/MDCK1 320 <10 640 320 160 640 B/Ireland/14244/2023 V1A.3a.2 2023-03-01 MDCK1 320 <10 640 320 320 640 B/Skovde/1/2023 V1A.3a.2 2023-03-01 SIAT1/MDCK1 320 <10 1280 320 320 320 B/Switzerland/20084/2023 V1A.3a.2 2023-03-03 MDCK1/MDCK1 320 <10 1280 320 320 320 B/Norway/3607/2023 V1A.3a.2 2023-03-06 MDCK1 160 <10 320 320 160 320 B/Sweden/4139/2023 V1A.3a.2 2023-03-06 SIAT1/MDCK1 320 10 640 320 320 640 B/Ireland/15857/2023 V1A.3a.2 2023-03-07 MDCK1 640 <10 640 640 320 640 B/Boras/1/2023 V1A.3a.2 2023-03-08 SIAT1/MDCK1 320 <10 1280 320 320 320 B/Norway/3989/2023 V1A.3a.2 2023-03-13 MDCK1 320 <10 640 320 160 640 B/Switzerland/213/2023 V1A.3a.2 2023-03-13 MDCK1/MDCK1 320 <10 640 320 320 640 B/Sweden/3764/2023 V1A.3a.2 2023-03-13 SIAT1/MDCK1 320 <10 640 320 160 640 B/Ireland/17764/2023 V1A.3a.2 2023-03-14 MDCK1 640 <10 640 640 320 1280 B/Norway/4000/2023 V1A.3a.2 2023-03-14 MDCK1 320 <10 1280 640 320 320 B/Piacenza/36/2023 V1A.3a.2 2023-03-14 MDCK3/MDCK1 320 <10 640 320 160 640 B/Ireland/18570/2023 V1A.3a.2 2023-03-16 MDCK1 640 <10 640 640 320 1280 B/Ireland/18976/2023 V1A.3a.2 2023-03-20 MDCK1 320 <10 640 320 160 640 B/Ireland/19288/2023 V1A.3a.2 2023-03-21 MDCK1 320 <10 640 320 320 640 B/Norway/5200/2023 V1A.3a.2 2023-03-28 MDCK1 320 <10 320 320 160 640 B/Norway/5216/2023 V1A.3a.2 2023-03-31 MDCK1 320 <10 1280 640 320 320 B/Norway/5172/2023 V1A.3a.2 2023-04-03 MDCK1 320 <10 640 320 320 640 B/Norway/5159/2023 V1A.3a.2 2023-04-03 MDCK1 320 <10 1280 640 320 640 B/Hungary/126/2023 V1A.3a.2 2023-04-03 MDCK1/MDCK1 320 <10 640 320 320 640 B/Serbia/2781/2023 V1A.3a.2 2023-04-03 C1/MDCK1 320 <10 640 320 160 320 B/Switzerland/55100/2023 V1A.3a.2 2023-04-06 SIAT1/MDCK1 320 <10 1280 320 320 320 B/Estonia/174086/2023 V1A.3a.2 2023-04-09 MDCK1 320 <10 640 320 160 320 B/BosniaAndHerzegovina/256/2023 V1A.3a.2 2023-04-11 MDCK1 320 <10 640 320 320 640 B/Sweden/5308/2023 V1A.3a.2 2023-04-13 SIAT1/MDCK1 320 10 640 320 320 640 B/Norway/5917/2023 V1A.3a.2 2023-04-14 MDCK1 640 <10 1280 640 320 1280 B/Serbia/3004/2023 V1A.3a.2 2023-04-16 C2/MDCK1 320 <10 640 160 160 320 B/BosniaAndHerzegovina/261/2023 V1A.3a.2 2023-04-18 MDCK1 320 <10 640 320 320 640 B/Sweden/5500/2023 V1A.3a.2 2023-04-23 SIAT1/MDCK1 320 <10 640 320 320 640 B/Sweden/5454/2023 V1A.3a.2 2023-04-24 SIAT1/MDCK1 320 10 640 320 160 640 B/Sweden/5553/2023 V1A.3a.2 2023-04-26 SIAT1/MDCK1 320 <10 640 320 160 320
Vaccine NH 2021-22
NH 2022-23 SH 2023
NH 2023-24
Haemagglutination inhibition titre Post-infection ferret antiserum
< relates to the lowest dilution of antiserum used Vaccine 1 hyperimmune sheep serum; ND = Not Done SH 2022
20
Table BV-15. Antigenic analyses of influenza B viruses (Victoria lineage) 2023-08-01
Viruses Other Collection Passage B/Bris B/Wash'ton B/Austria B/Austria B/Austria B/Stock information date history 60/08 02/19 1359417/21 1359417/21 1359417/21 3/22
Passage history Egg Egg MDCK Egg G141 Egg G141R MDCK
Ferret number
Sh 539, 540, 543, 544, 570, 571, 5741
F20/20 NIB F01/21 F15/21 F44/21 F28/22
Genetic group V1A V1A.3 V1A.3a.2 V1A.3a.2 V1A.3a.2 V1A.3a.2
REFERENCE VIRUSES B/Brisbane/60/2008 V1A 2008-08-04 E4/E4 2560 80 <40 <40 <40 <40 B/Washington/02/2019 V1A.3 2019-01-19 E3/E3 640 160 <40 <40 <40 <40 B/Austria/1359417/2021 G141 V1A.3a.2 2021-01-09 SIAT1/MDCK4 320 10 1280 640 320 640 B/Austria/1359417/2021 Isolate 2 G141 V1A.3a.2 2021-01-09 E3/E4 160 10 2560 640 640 640 B/Austria/1359417/2021 Isolate 2 G141R V1A.3a.2 2021-01-09 E3/E5 320 10 1280 640 2560 640 B/Stockholm/3/2022 V1A.3a.2 2022-03-22 SIAT1/MDCK3 640 10 1280 640 320 640 TEST VIRUSES B/Parma/8/2023 V1A.3a.2 2023-02-01 MDCK1/MDCK1 320 <10 640 320 320 640 B/FVG-Gorizia/34/2023 V1A.3a.2 2023-02-01 MDCK1/MDCK1 640 10 1280 640 320 320 B/FVG-Gorizia/33/2023 V1A.3a.2 2023-02-01 MDCK1/MDCK1 640 10 1280 640 320 1280 B/Belgium/S1509/2023 V1A.3a.2 2023-02-01 MDCK1/MDCK1 640 10 640 320 320 640 B/Belgium/G0178/2023 V1A.3a.2 2023-02-02 MDCK1/MDCK1 640 10 640 320 320 640 B/Belgium/G0192/2023 V1A.3a.2 2023-02-03 MDCK1/MDCK1 320 10 640 320 320 640 B/Belgium/G0182/2023 V1A.3a.2 2023-02-06 MDCK1/MDCK1 640 10 1280 640 320 1280 B/Belgium/S1322/2023 V1A.3a.2 2023-02-07 MDCK1/MDCK1 640 10 640 640 320 640 B/Belgium/G0187/2023 V1A.3a.2 2023-02-07 MDCK1/MDCK1 640 10 640 640 320 640 B/Belgium/S1167/2023 V1A.3a.2 2023-02-09 MDCK1/MDCK1 320 <10 640 640 320 640 B/Belgium/S1674/2023 V1A.3a.2 2023-02-12 MDCK1/MDCK1 320 10 1280 640 640 640 B/Belgium/S1273/2023 V1A.3a.2 2023-02-13 MDCK1/MDCK1 320 10 640 320 320 640 B/Belgium/S1782/2023 V1A.3a.2 2023-02-14 MDCK1/MDCK1 640 10 2560 640 640 640 B/Ireland/11305/2023 V1A.3a.2 2023-02-15 MDCK1 640 10 1280 1280 320 1280 B/Belgium/S1933/2023 V1A.3a.2 2023-02-21 MDCK1/MDCK1 640 10 1280 640 320 640 B/Belgium/G0231/2023 V1A.3a.2 2023-02-21 MDCK1/MDCK1 640 10 640 640 320 640 B/Belgium/S1960/2023 V1A.3a.2 2023-02-22 MDCK1/MDCK1 640 10 1280 640 640 640 B/Belgium/S1397/2023 V1A.3a.2 2023-02-23 MDCK1/MDCK1 640 10 2560 640 640 640 B/Belgium/S1957/2023 V1A.3a.2 2023-02-26 MDCK1/MDCK1 640 10 640 640 320 640 B/Belgium/S1420/2023 V1A.3a.2 2023-02-27 MDCK1/MDCK1 640 10 1280 640 320 640 B/Belgium/G0282/2023 V1A.3a.2 2023-03-16 MDCK1/MDCK1 640 10 1280 640 320 1280 B/Poland/157/2023 V1A.3a.2 2023-03-29 MDCK1 640 10 2560 1280 640 640 B/Estonia/KL484/2023 V1A.3a.2 2023-04-04 MDCK2 1280 20 1280 1280 640 1280
Vaccine NH 2021-22
NH 2022-23 SH 2023
NH 2023-24
Haemagglutination inhibition titre Post-infection ferret antiserum
< relates to the lowest dilution of antiserum used Vaccine 1 hyperimmune sheep serum; ND = Not Done SH 2022
21
Table BV-17. Antigenic analyses of influenza B viruses (Victoria lineage) 2023-08-15
Viruses Other Collection Passage B/Bris B/Wash'ton B/Austria B/Austria B/Austria B/Stock information date history 60/08 02/19 1359417/21 1359417/21 1359417/21 3/22
Passage history Egg Egg MDCK Egg G141 Egg G141R MDCK
Ferret number
Sh 539, 540, 543, 544, 570, 571, 5741
F20/20 NIB F01/21 F15/21 F44/21 F28/22
Genetic group V1A V1A.3 V1A.3a.2 V1A.3a.2 V1A.3a.2 V1A.3a.2
REFERENCE VIRUSES B/Brisbane/60/2008 V1A 2008-08-04 E4/E4 2560 160 <40 <40 <40 <40 B/Washington/02/2019 V1A.3 2019-01-19 E3/E3 640 320 <40 <40 <40 <40 B/Austria/1359417/2021 G141 V1A.3a.2 2021-01-09 SIAT1/MDCK4 320 20 1280 640 320 320 B/Austria/1359417/2021 Isolate 2 G141 V1A.3a.2 2021-01-09 E3/E4 640 20 1280 640 640 640 B/Austria/1359417/2021 Isolate 2 G141R V1A.3a.2 2021-01-09 E3/E5 320 20 1280 640 2560 640 B/Stockholm/3/2022 V1A.3a.2 2022-03-22 SIAT1/MDCK3 640 10 640 640 320 640 TEST VIRUSES B/Estonia/173317/2023 V1A.3a.2 2023-02-03 MDCK1 640 20 640 640 320 640 B/Estonia/173429/2023 V1A.3a.2 2023-02-15 MDCK1 640 20 1280 640 320 320 B/Estonia/173580/2023 V1A.3a.2 2023-02-22 MDCK1 640 20 1280 640 320 640 B/Estonia/173587/2023 V1A.3a.2 2023-02-27 MDCK1 640 20 1280 640 320 320 B/Estonia/173777/2023 V1A.3a.2 2023-03-07 MDCK1 1280 40 1280 640 320 640 B/Estonia/173928/2023 V1A.3a.2 2023-03-23 MDCK1 1280 40 1280 1280 640 640 B/Estonia/173900/2023 V1A.3a.2 2023-03-25 MDCK1 640 20 1280 640 320 640 B/Estonia/173585/2023 V1A.3a.2 2023-03-27 MDCK1 1280 40 1280 640 640 640 B/Romania/550752/2023 V1A.3a.2 2023-04-21 SIAT1/MDCK1 320 10 640 320 320 320 B/Burgos/4840/2023 V1A.3a.2 2023-04-25 MDCK1 640 20 640 640 320 640 B/Avila/4883/2023 V1A.3a.2 2023-04-29 MDCK1 1280 20 1280 640 320 640 B/Palencia/4842/2023 V1A.3a.2 2023-05-03 MDCK1 1280 40 1280 640 640 640 B/Salamanca/4852/2023 V1A.3a.2 2023-05-05 MDCK1 1280 40 1280 640 640 640 B/Salamanca/4851/2023 V1A.3a.2 2023-05-05 MDCK1 640 20 1280 640 320 640 B/Burgos/4893/2023 V1A.3a.2 2023-05-08 MDCK1 1280 20 1280 640 320 640 B/Segovia/4864/2023 V1A.3a.2 2023-05-10 MDCK1 640 20 1280 640 320 640 B/Leon/4901/2023 V1A.3a.2 2023-05-16 MDCK1 640 20 1280 640 640 640 B/HongKong/15/2023 V1A.3a.2 2023-06-17 MDCK1/MDCK1 640 20 640 640 320 640
Vaccine NH 2021-22
NH 2022-23 SH 2023
NH 2023-24
Haemagglutination inhibition titre Post-infection ferret antiserum
< relates to the lowest dilution of antiserum used Vaccine 1 hyperimmune sheep serum; ND = Not Done SH 2022
22
Viruses Other B/Bris B/Wash'ton B/Austria B/Austria B/Austria B/Stock information 60/08 02/19 1359417/21 1359417/21 1359417/21 3/22
Passage Egg Egg MDCK Egg G141 Egg G141R MDCK
Ferret number
Sh 539, 540, 543, 544, 570, 571, 5741
F20/20 NIB F01/21 F40/21 F44/21 F28/22
COPY AND PASTE VALUES!! Genetic group Collection Date Genetic group V1A V1A.3 V1A.3a.2 V1A.3a.2 V1A.3a.2 V1A.3a.2
REFERENCE VIRUSES B/Brisbane/60/2008 V1A 2008-08-04 E4/E4 1280 40 <40 <40 <40 <40 B/Washington/02/2019 V1A.3 2019-01-19 E3/E3 640 160 40 <40 <40 <40 B/Austria/1359417/2021 A127T, P144L, K302R (G141) V1A.3a.2 2021-01-09 SIAT1/MDCK4 640 <10 1280 640 320 320 B/Austria/1359417/2021 Isolate 2 A127T, P144L, K302R (G141) V1A.3a.2 2021-01-09 E3/E4 320 <10 1280 640 320 320 B/Austria/1359417/2021 Isolate 2 A127T, P144L, K302R (G141R) V1A.3a.2 2021-01-09 E3/E5 160 <10 1280 320 2560 320 B/Stockholm/3/2022 D129G, E183K, D197E V1A.3a.2 2022-03-22 SIAT1/MDCK3 320 <10 640 320 320 640
TEST VIRUSES 235467 B/Bratislava/155/2023 V1A.3a.2 2023-02-21 MDCK2 320 <10 640 320 160 320 233836 B/Estonia/173671/2023 V1A.3a.2 2023-03-04 MDCK1 640 10 1280 640 320 320 234127 B/Poland/123/2023 V1A.3a.2 2023-03-05 MDCK1 320 <10 1280 640 320 320 234126 B/Poland/143/2023 V1A.3a.2 2023-03-06 MDCK1 320 <10 640 640 320 640 233834 B/Estonia/173722/2023 V1A.3a.2 2023-03-07 MDCK1 640 <10 640 320 320 640 234120 B/Poland/135/2023 V1A.3a.2 2023-03-08 MDCK1 320 <10 1280 640 320 320 234121 B/Poland/126/2023 V1A.3a.2 2023-03-08 MDCK1 320 <10 1280 640 320 320 234116 B/Poland/142/2023 V1A.3a.2 2023-03-09 MDCK1 320 <10 1280 640 320 320 234113 B/Poland/137/2023 V1A.3a.2 2023-03-11 MDCK1 320 <10 640 320 160 640 234110 B/Poland/161/2023 V1A.3a.2 2023-03-12 MDCK1 640 <10 1280 640 320 640 234111 B/Poland/140/2023 V1A.3a.2 2023-03-12 MDCK1 320 <10 1280 640 320 320 234106 B/Poland/134/2023 V1A.3a.2 2023-03-14 MDCK1 640 10 640 640 320 640 235581 B/Cat/3520958NS/2023 V1A.3a.2 2023-03-19 P0/MDCK1 320 10 640 320 160 320 234077 B/Poland/189/2023 V1A.3a.2 2023-03-21 MDCK1 640 <10 640 320 320 640 234143 B/Poland/102/2023 V1A.3a.2 2023-03-27 MDCK1 640 <10 640 320 320 640 235578 B/Cat/3521492NS/2023 V1A.3a.2 2023-03-27 P0/MDCK1 640 <10 640 320 160 320 234139 B/Poland/99/2023 V1A.3a.2 2023-03-31 MDCK1 320 <10 640 640 320 640 234137 B/Poland/96/2023 V1A.3a.2 2023-04-05 MDCK1 640 <10 640 320 160 640 235580 B/Cat/3522202NS/2023 V1A.3a.2 2023-04-06 P0/MDCK1 320 <10 320 320 160 320 235579 B/Cat/3522555NS/2023 V1A.3a.2 2023-04-11 P0/MDCK1 320 <10 640 320 320 320 235577 B/Cat/3522776NS/2023 V1A.3a.2 2023-04-15 P0/MDCK1 320 <10 640 320 160 320 235576 B/Cat/2025676NS/2023 V1A.3a.2 2023-04-19 P0/MDCK1 320 <10 1280 640 320 320 234234 B/Burgos/4894/2023 V1A.3a.2 2023-05-08 MDCK1 320 <10 640 320 320 640 235571 B/Denmark/1846/2023 V1A.3a.2 2023-05-08 SIAT2/MDCK1 320 <10 640 320 160 320 235575 B/Cat/3524181NS/2023 V1A.3a.2 2023-05-08 P0/MDCK1 320 <10 640 640 320 640 235574 B/Cat/3525527NS/2023 V1A.3a.2 2023-05-29 P0/MDCK1 640 <10 640 320 320 320 235570 B/Denmark/1854/2023 V1A.3a.2 2023-06-02 SIAT2/MDCK1 320 <10 640 320 160 640
Vaccine NH 2021-22
Table BV-21. Antigenic analyses of influenza B viruses (Victoria lineage) 2023-09-27
NH 2022-23 SH 2023
NH 2023-24
Haemagglutination inhibition titre
Post-infection ferret antiserum
< relates to the lowest dilution of antiserum used Vaccine 1 hyperimmune sheep serum; ND = Not Done SH 2022
23
Summary of sample characterisation We follow a sequencing‑first approach where we sequence all the clinical samples, with further selection of samples for isolation in cell culture and antigenic characterisation based on representative genetic diversity. Samples with identical sequences may not be selected for further characterisation.
Antigenic characterisation Genetic characterisation Antiviral susceptibility phenotypic testing
Virus name Original passage sent Collection date Type/Subtype Date received HI table date HI comments WIC Passage history Genetic clade Submitted to GISAID EPI Accession Sequencing comments Oseltamivir Zanamivir Baloxavir marboxil
B/Estonia/173034/2023 cs 2023‑01‑23 BV 2023‑02‑06 Virus not recovered cs V1A.3a.2 2023‑03‑16 17225766 B/Estonia/173044/2023 cs 2023‑01‑20 BV 2023‑02‑06 2023‑06‑01 cs V1A.3a.2 2023‑03‑16 17225841 Normal inhibition Normal inhibition B/Estonia/173044/2023 cs 2023‑01‑20 BV 2023‑02‑06 2023‑06‑01 MDCK1 V1A.3a.2 2023‑06‑21 17820100 Normal inhibition Normal inhibition B/Estonia/172315/2022 cs 2022‑12‑05 BV 2023‑02‑06 2023‑06‑01 cs V1A.3a.2 2023‑03‑16 17225840 Normal inhibition Normal inhibition B/Estonia/172315/2022 cs 2022‑12‑05 BV 2023‑02‑06 2023‑06‑01 MDCK1 V1A.3a.2 2023‑06‑21 17820101 Normal inhibition Normal inhibition B/Estonia/172050/2022 cs 2022‑12‑01 BV 2023‑02‑06 2023‑06‑01 cs V1A.3a.2 2023‑03‑16 17225768 Normal inhibition Normal inhibition B/Estonia/172050/2022 cs 2022‑12‑01 BV 2023‑02‑06 2023‑06‑01 MDCK1 V1A.3a.2 2023‑06‑21 17820102 Normal inhibition Normal inhibition A/Estonia/173037/2023 cs 2023‑01‑23 H1pdm 2023‑02‑06 2023‑06‑01 cs 5a.2a 2023‑03‑16 17225340 A/Estonia/173037/2023 cs 2023‑01‑23 H1pdm 2023‑02‑06 2023‑06‑01 MDCK1 5a.2a 2023‑06‑21 17820129 A/Estonia/172995/2023 cs 2023‑01‑21 H1pdm 2023‑02‑06 Identical sequence – not cultured cs 5a.2a 2023‑03‑16 17225329 A/Estonia/172997/2023 cs 2023‑01‑18 H1pdm 2023‑02‑06 2023‑06‑01 cs no sequence Normal inhibition Normal inhibition A/Estonia/172997/2023 cs 2023‑01‑18 H1pdm 2023‑02‑06 2023‑06‑01 MDCK2 5a.2a 2023‑06‑21 17820130 Normal inhibition Normal inhibition A/Estonia/172935/2023 cs 2023‑01‑15 H1pdm 2023‑02‑06 Failed sequence – not cultured cs no sequence A/Estonia/172882/2023 cs 2023‑01‑15 H1pdm 2023‑02‑06 Virus not recovered cs 5a.2a.1 2023‑03‑16 17225293 A/Estonia/172881/2023 cs 2023‑01‑15 H1pdm 2023‑02‑06 2023‑06‑01 cs no sequence Normal inhibition Normal inhibition A/Estonia/172881/2023 cs 2023‑01‑15 H1pdm 2023‑02‑06 2023‑06‑01 MDCK1 5a.2a 2023‑06‑21 17820131 Normal inhibition Normal inhibition A/Estonia/172786/2023 cs 2023‑01‑10 H1pdm 2023‑02‑06 Identical sequence – not cultured cs 5a.2a.1 2023‑03‑16 17225306 A/Estonia/KL51/2023 cs 2023‑01‑09 H1pdm 2023‑02‑06 Identical sequence – not cultured cs 5a.2a 2023‑03‑16 17225305 A/Estonia/172762/2023 cs 2023‑01‑09 H1pdm 2023‑02‑06 Identical sequence – not cultured cs 5a.2a 2023‑03‑16 17225304 A/Estonia/172757/2023 cs 2023‑01‑09 H1pdm 2023‑02‑06 cs 5a.2a 2023‑03‑16 17225303 A/Estonia/172759/2023 cs 2023‑01‑06 H1pdm 2023‑02‑06 Identical sequence – not cultured cs 5a.2a 2023‑03‑16 17225302 A/Estonia/KL26/2023 cs 2023‑01‑04 H1pdm 2023‑02‑06 Identical sequence – not cultured cs 5a.2a 2023‑03‑16 17225301 A/Estonia/172644/2022 cs 2022‑12‑27 H1pdm 2023‑02‑06 Identical sequence – not cultured cs 5a.2a 2023‑03‑16 17225292 A/Estonia/172548/2022 cs 2022‑12‑27 H1pdm 2023‑02‑06 2023‑06‑01 cs no sequence Normal inhibition Normal inhibition A/Estonia/172548/2022 cs 2022‑12‑27 H1pdm 2023‑02‑06 2023‑06‑01 MDCK1 5a.2a 2023‑06‑21 17820132 Normal inhibition Normal inhibition A/Estonia/172492/2022 cs 2022‑12‑26 H1pdm 2023‑02‑06 Identical sequence – not cultured cs 5a.2a.1 2023‑03‑16 17225299 A/Estonia/172516/2022 cs 2022‑12‑21 H1pdm 2023‑02‑06 Identical sequence – not cultured cs 5a.2a 2023‑03‑16 17225307 A/Estonia/KL7228/2022 cs 2022‑12‑20 H1pdm 2023‑02‑06 2023‑06‑01 cs 5a.2a 2023‑03‑16 17225316 Normal inhibition Normal inhibition A/Estonia/KL7228/2022 cs 2022‑12‑20 H1pdm 2023‑02‑06 2023‑06‑01 MDCK1 5a.2a 2023‑06‑21 17820133 Normal inhibition Normal inhibition A/Estonia/KL7227/2022 cs 2022‑12‑20 H1pdm 2023‑02‑06 Virus not recovered cs 5a.2a.1 2023‑03‑16 17225297 A/Estonia/KL7227/2022 cs 2022‑12‑20 H1pdm 2023‑02‑06 Virus not recovered MDCK1 A/Estonia/KL7114/2022 cs 2022‑12‑13 H1pdm 2023‑02‑06 Virus not recovered cs no sequence A/Estonia/KL7103/2022 cs 2022‑12‑13 H1pdm 2023‑02‑06 Virus not recovered cs 5a.2a 2023‑03‑16 17225327 A/Estonia/KL7088/2022 cs 2022‑12‑13 H1pdm 2023‑02‑06 Identical sequence – not cultured cs 5a.2a 2023‑03‑16 17225295 A/Estonia/172371/2022 cs 2022‑12‑13 H1pdm 2023‑02‑06 Identical sequence – not cultured cs 5a.2a 2023‑02‑28 17049195 A/Estonia/172163/2022 cs 2022‑12‑09 H1pdm 2023‑02‑06 Failed sequence – not cultured cs no sequence A/Estonia/172049/2022 cs 2022‑12‑01 H1pdm 2023‑02‑06 Identical sequence – not cultured cs 5a.2a 2023‑02‑28 17049191 A/Estonia/171861/2022 cs 2022‑11‑25 H1pdm 2023‑02‑06 Failed sequence – not cultured cs no sequence A/Estonia/173038/2023 cs 2023‑01‑23 H3 2023‑02‑06 2023‑05‑26 cs 2b 2023‑02‑28 17049162 Normal inhibition Normal inhibition A/Estonia/173038/2023 cs 2023‑01‑23 H3 2023‑02‑06 2023‑05‑26 SIAT1 2b 2023‑06‑21 17820162 Normal inhibition Normal inhibition A/Estonia/173028/2023 cs 2023‑01‑21 H3 2023‑02‑06 2023‑05‑26 cs no sequence Insufficient Titre Insufficient Titre A/Estonia/173028/2023 cs 2023‑01‑21 H3 2023‑02‑06 2023‑05‑26 SIAT1 2b 2023‑06‑21 17820163 Insufficient Titre Insufficient Titre A/Estonia/173098/2023 cs 2023‑01‑19 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049161 A/Estonia/172883/2023 cs 2023‑01‑13 H3 2023‑02‑06 2023‑05‑26 cs 2a.1b 2023‑02‑28 17049160 Normal inhibition Normal inhibition A/Estonia/172883/2023 cs 2023‑01‑13 H3 2023‑02‑06 2023‑05‑26 SIAT1 2a.1b 2023‑06‑21 17820164 Normal inhibition Normal inhibition A/Estonia/172886/2023 cs 2023‑01‑11 H3 2023‑02‑06 2023‑05‑26 cs 2a.1b 2023‑02‑28 17049159 Normal inhibition Normal inhibition A/Estonia/172886/2023 cs 2023‑01‑11 H3 2023‑02‑06 2023‑05‑26 SIAT1 2a.1b 2023‑06‑21 17820165 Normal inhibition Normal inhibition A/Estonia/172892/2023 cs 2023‑01‑10 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049158 A/Estonia/KL34/2023 cs 2023‑01‑05 H3 2023‑02‑06 Failed sequence – not cultured cs no sequence A/Estonia/172629/2023 cs 2023‑01‑02 H3 2023‑02‑06 2023‑06‑09 cs no sequence Normal inhibition Normal inhibition A/Estonia/172629/2023 cs 2023‑01‑02 H3 2023‑02‑06 2023‑06‑09 SIAT2 2a.1b 2023‑06‑21 17820166 Normal inhibition Normal inhibition A/Estonia/172610/2023 cs 2023‑01‑02 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049157 A/Estonia/172691/2023 cs 2023‑01‑01 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049143 A/Estonia/172631/2023 cs 2023‑01‑01 H3 2023‑02‑06 2023‑05‑26 cs 2a.1b 2023‑02‑28 17049155 Normal inhibition Normal inhibition A/Estonia/172631/2023 cs 2023‑01‑01 H3 2023‑02‑06 2023‑05‑26 SIAT1 2a.1b 2023‑06‑21 17820167 Normal inhibition Normal inhibition A/Estonia/172630/2023 cs 2023‑01‑01 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049168 A/Estonia/KL3 /2022 cs 2022‑12‑30 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049153 A/Estonia/KL7285/2022 cs 2022‑12‑28 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑02‑28 17049152 A/Estonia/KL7277/2022 cs 2022‑12‑28 H3 2023‑02‑06 2023‑05‑26 cs 2a.1b 2023‑02‑28 17049170 Normal inhibition Normal inhibition
24
(continued)
Antigenic characterisation Genetic characterisation Antiviral susceptibility phenotypic testing
Virus name Original passage sent Collection date Type/Subtype Date received HI table date HI comments WIC Passage history Genetic clade Submitted to GISAID EPI Accession Sequencing comments Oseltamivir Zanamivir Baloxavir marboxil
A/Estonia/KL7277/2022 cs 2022‑12‑28 H3 2023‑02‑06 2023‑05‑26 SIAT1 2a.1b 2023‑06‑21 17820168 Normal inhibition Normal inhibition A/Estonia/172639/2022 cs 2022‑12‑27 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑02‑28 17049151 A/Estonia/172547/2022 cs 2022‑12‑27 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049156 A/Estonia/172543/2022 cs 2022‑12‑25 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑02‑28 17049150 A/Estonia/172575/2022 cs 2022‑12‑24 H3 2023‑02‑06 2023‑05‑26 cs 2b 2023‑02‑28 17049149 Normal inhibition Normal inhibition A/Estonia/172575/2022 cs 2022‑12‑24 H3 2023‑02‑06 2023‑05‑26 SIAT1 2b 2023‑06‑21 17820169 Normal inhibition Normal inhibition A/Estonia/172487/2022 cs 2022‑12‑24 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049148 A/Estonia/KL7231/2022 cs 2022‑12‑22 H3 2023‑02‑06 Virus not recovered cs 2b 2023‑02‑28 17049147 A/Estonia/172466/2022 cs 2022‑12‑21 H3 2023‑02‑06 Virus not recovered cs no sequence A/Estonia/172464/2022 cs 2022‑12‑19 H3 2023‑02‑06 2023‑05‑26 cs 2a.1b 2023‑02‑28 17049146 Normal inhibition Normal inhibition A/Estonia/172464/2022 cs 2022‑12‑19 H3 2023‑02‑06 2023‑05‑26 SIAT1 2a.1b 2023‑06‑21 17820170 Normal inhibition Normal inhibition A/Estonia/172379/2022 cs 2022‑12‑19 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049145 A/Estonia/KL7133/2022 cs 2022‑12‑14 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049144 A/Estonia/172437/2022 cs 2022‑12‑14 H3 2023‑02‑06 2023‑05‑26 cs 2a.1b 2023‑02‑28 17049154 Normal inhibition Normal inhibition A/Estonia/172437/2022 cs 2022‑12‑14 H3 2023‑02‑06 2023‑05‑26 SIAT1 2a.1b 2023‑06‑21 17820171 Normal inhibition Normal inhibition A/Estonia/172436/2022 cs 2022‑12‑13 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049171 A/Estonia/172394/2022 cs 2022‑12‑13 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049188 A/Estonia/172051/2022 cs 2022‑12‑13 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049187 A/Estonia/KL7045/2022 cs 2022‑12‑12 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑02‑28 17049186 A/Estonia/172366/2022 cs 2022‑12‑12 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049185 A/Estonia/172236/2022 cs 2022‑12‑11 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049184 A/Estonia/172195/2022 cs 2022‑12‑11 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049183 A/Estonia/172172/2022 cs 2022‑12‑10 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049182 A/Estonia/172187/2022 cs 2022‑12‑09 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049181 A/Estonia/172181/2022 cs 2022‑12‑09 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑02‑28 17049180 A/Estonia/172219/2022 cs 2022‑12‑08 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049169 A/Estonia/172138/2022 cs 2022‑12‑07 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049179 A/Estonia/172137/2022 cs 2022‑12‑07 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑02‑28 17049189 A/Estonia/172107/2022 cs 2022‑12‑07 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑02‑28 17049178 A/Estonia/172106/2022 cs 2022‑12‑07 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049177 A/Estonia/172111/2022 cs 2022‑12‑06 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049176 A/Estonia/172078/2022 cs 2022‑12‑06 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑02‑28 17049175 A/Estonia/172077/2022 cs 2022‑12‑06 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑02‑28 17049174 A/Estonia/172074/2022 cs 2022‑12‑06 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑03‑16 17223835 A/Estonia/172058/2022 cs 2022‑12‑05 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑03‑16 17223849 A/Estonia/172053/2022 cs 2022‑12‑05 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑03‑16 17223864 A/Estonia/172016/2022 cs 2022‑12‑05 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑03‑16 17223847 A/Estonia/172034/2022 cs 2022‑12‑04 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑03‑16 17223846 A/Estonia/172023/2022 cs 2022‑12‑04 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑03‑16 17223845 A/Estonia/172009/2022 cs 2022‑12‑04 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑03‑16 17223844 A/Estonia/172022/2022 cs 2022‑12‑03 H3 2023‑02‑06 Virus not recovered cs no sequence A/Estonia/KL6953/2022 cs 2022‑12‑02 H3 2023‑02‑06 Virus not recovered cs 2a.1 2023‑03‑16 17223842 A/Estonia/171948/2022 cs 2022‑11‑30 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑03‑16 17223841 A/Estonia/171947/2022 cs 2022‑11‑30 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑03‑16 17223840 A/Estonia/171943/2022 cs 2022‑11‑29 H3 2023‑02‑06 Virus not recovered cs no sequence A/Estonia/171921/2022 cs 2022‑11‑29 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑03‑16 17223839 A/Estonia/171919/2022 cs 2022‑11‑29 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑03‑16 17223838 A/Estonia/171918/2022 cs 2022‑11‑29 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑03‑16 17223837 A/Estonia/171881/2022 cs 2022‑11‑28 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑03‑16 17223836 A/Estonia/171880/2022 cs 2022‑11‑28 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑03‑16 17223882 A/Estonia/171884/2022 cs 2022‑11‑27 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑03‑16 17223894 A/Estonia/171888/2022 cs 2022‑11‑26 H3 2023‑02‑06 Failed sequence – not cultured cs no sequence A/Estonia/171890/2022 cs 2022‑11‑25 H3 2023‑02‑06 Failed sequence – not cultured cs no sequence A/Estonia/171834/2022 cs 2022‑11‑24 H3 2023‑02‑06 Identical sequence – not cultured cs 2a.1b 2023‑03‑16 17223850 A/Estonia/171793/2022 cs 2022‑11‑22 H3 2023‑02‑06 Identical sequence – not cultured cs 2b 2023‑03‑16 17223965 A/Estonia/171754/2022 cs 2022‑11‑18 H3 2023‑02‑06 Failed sequence – not cultured cs no sequence B/Estonia/174160/2023 cs 2023‑04‑16 BV 2023‑05‑15 Virus not recovered cs V1A.3a.2 2023‑07‑20 18007288 B/Estonia/174162/2023 cs 2023‑04‑15 BV 2023‑05‑15 Virus not recovered cs no sequence B/Estonia/174161/2023 cs 2023‑04‑15 BV 2023‑05‑15 Virus not recovered cs V1A.3a.2 2023‑07‑20 18007289 B/Estonia/174174/2023 cs 2023‑04‑14 BV 2023‑05‑15 2023‑05‑24 cs V1A.3a.2 2023‑07‑20 18007290 Normal inhibition Normal inhibition B/Estonia/174174/2023 cs 2023‑04‑14 BV 2023‑05‑15 2023‑05‑24 MDCK1 V1A.3a.2 2023‑07‑20 18008416 Normal inhibition Normal inhibition B/Estonia/KL549/2023 cs 2023‑04‑13 BV 2023‑05‑15 2023‑05‑24 cs V1A.3a.2 2023‑07‑20 18007291 Normal inhibition Normal inhibition B/Estonia/KL549/2023 cs 2023‑04‑13 BV 2023‑05‑15 2023‑05‑24 MDCK1 V1A.3a.2 2023‑07‑20 18008418 Normal inhibition Normal inhibition B/Estonia/KL548/2023 cs 2023‑04‑13 BV 2023‑05‑15 2023‑05‑24 cs V1A.3a.2 2023‑06‑21 17820224 Normal inhibition Normal inhibition B/Estonia/KL548/2023 cs 2023‑04‑13 BV 2023‑05‑15 2023‑05‑24 MDCK1 no sequence Normal inhibition Normal inhibition B/Estonia/174175/2023 cs 2023‑04‑12 BV 2023‑05‑15 2023‑05‑24 cs V1A.3a.2 2023‑06‑21 17820213 Normal inhibition Normal inhibition B/Estonia/174175/2023 cs 2023‑04‑12 BV 2023‑05‑15 2023‑05‑24 MDCK1 V1A.3a.2 2023‑07‑20 18008417 Normal inhibition Normal inhibition
25
(continued)
Antigenic characterisation Genetic characterisation Antiviral susceptibility phenotypic testing
Virus name Original passage sent Collection date Type/Subtype Date received HI table date HI comments WIC Passage history Genetic clade Submitted to GISAID EPI Accession Sequencing comments Oseltamivir Zanamivir Baloxavir marboxil
B/Estonia/KL506/2023 cs 2023‑04‑11 BV 2023‑05‑15 Virus not recovered cs no sequence B/Estonia/KL503/2023 cs 2023‑04‑11 BV 2023‑05‑15 Virus not recovered cs no sequence B/Estonia/174172/2023 cs 2023‑04‑11 BV 2023‑05‑15 2023‑05‑24 cs V1A.3a.2 2023‑06‑21 17820220 Normal inhibition Normal inhibition B/Estonia/174172/2023 cs 2023‑04‑11 BV 2023‑05‑15 2023‑05‑24 MDCK1 no sequence Normal inhibition Normal inhibition B/Estonia/KL499/2023 cs 2023‑04‑10 BV 2023‑05‑15 Virus not recovered cs no sequence B/Estonia/KL497/2023 cs 2023‑04‑10 BV 2023‑05‑15 Virus not recovered cs no sequence B/Estonia/KL492/2023 cs 2023‑04‑10 BV 2023‑05‑15 Virus not recovered cs V1A.3a.2 2023‑06‑21 17820219 B/Estonia/174084/2023 cs 2023‑04‑10 BV 2023‑05‑15 Virus not recovered cs V1A.3a.2 2023‑06‑21 17820218 B/Estonia/174086/2023 cs 2023‑04‑09 BV 2023‑05‑15 2023‑07‑25 cs V1A.3a.2 2023‑06‑21 17820217 Normal inhibition Normal inhibition B/Estonia/174086/2023 cs 2023‑04‑09 BV 2023‑05‑15 2023‑07‑25 MDCK1 V1A.3a.2 2023‑08‑31 18167128 Normal inhibition Normal inhibition B/Estonia/KL490/2023 cs 2023‑04‑06 BV 2023‑05‑15 Virus not recovered cs no sequence B/Estonia/174088/2023 cs 2023‑04‑06 BV 2023‑05‑15 Virus not recovered cs V1A.3a.2 2023‑06‑21 17820216 B/Estonia/KL482/2023 cs 2023‑04‑05 BV 2023‑05‑15 Virus not recovered cs V1A.3a.2 2023‑06‑21 17820215 B/Estonia/KL484/2023 cs 2023‑04‑04 BV 2023‑05‑15 2023‑08‑01 cs V1A.3a.2 2023‑06‑21 17820209 Normal inhibition Normal inhibition B/Estonia/KL484/2023 cs 2023‑04‑04 BV 2023‑05‑15 2023‑08‑01 MDCK2 V1A.3a.2 2023‑08‑31 18167424 Normal inhibition Normal inhibition B/Estonia/174044/2023 cs 2023‑04‑04 BV 2023‑05‑15 Virus not recovered cs V1A.3a.2 2023‑06‑21 17820214 B/Estonia/173949/2023 cs 2023‑03‑27 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820223 B/Estonia/173930/2023 cs 2023‑03‑27 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820203 B/Estonia/173585/2023 cs 2023‑03‑27 BV 2023‑05‑15 2023‑08‑15 cs V1A.3a.2 2023‑06‑21 17820204 Normal inhibition Normal inhibition B/Estonia/173585/2023 cs 2023‑03‑27 BV 2023‑05‑15 2023‑08‑15 MDCK1 V1A.3a.2 2023‑09‑06 18226849 Normal inhibition Normal inhibition B/Estonia/173905/2023 cs 2023‑03‑25 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820205 B/Estonia/173901/2023 cs 2023‑03‑25 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820206 B/Estonia/173900/2023 cs 2023‑03‑25 BV 2023‑05‑15 2023‑08‑15 cs V1A.3a.2 2023‑06‑21 17820207 Normal inhibition Normal inhibition B/Estonia/173900/2023 cs 2023‑03‑25 BV 2023‑05‑15 2023‑08‑15 MDCK1 V1A.3a.2 2023‑09‑06 18226850 Normal inhibition Normal inhibition B/Estonia/173929/2023 cs 2023‑03‑23 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820212 B/Estonia/173928/2023 cs 2023‑03‑23 BV 2023‑05‑15 2023‑08‑15 cs V1A.3a.2 2023‑06‑21 17820208 Normal inhibition Normal inhibition B/Estonia/173928/2023 cs 2023‑03‑23 BV 2023‑05‑15 2023‑08‑15 MDCK1 V1A.3a.2 2023‑09‑06 18226851 Normal inhibition Normal inhibition B/Estonia/KL432/2023 cs 2023‑03‑20 BV 2023‑05‑15 Virus not recovered cs no sequence B/Estonia/173845/2023 cs 2023‑03‑18 BV 2023‑05‑15 Virus not recovered cs no sequence B/Estonia/173850/2023 cs 2023‑03‑17 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820202 B/Estonia/KL392/2023 cs 2023‑03‑16 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820210 B/Estonia/173777/2023 cs 2023‑03‑07 BV 2023‑05‑15 2023‑08‑15 cs V1A.3a.2 2023‑06‑21 17820211 Normal inhibition Normal inhibition B/Estonia/173777/2023 cs 2023‑03‑07 BV 2023‑05‑15 2023‑08‑15 MDCK1 V1A.3a.2 2023‑09‑06 18226852 Normal inhibition Normal inhibition B/Estonia/173722/2023 cs 2023‑03‑07 BV 2023‑05‑15 2023‑09‑27 cs V1A.3a.2 2023‑06‑21 17820221 Normal inhibition Normal inhibition Normal inhibition B/Estonia/173722/2023 cs 2023‑03‑07 BV 2023‑05‑15 2023‑09‑27 MDCK1 V1A.3a.2 2023‑10‑24 18430755 Normal inhibition Normal inhibition Normal inhibition B/Estonia/173617/2023 cs 2023‑03‑07 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820236 B/Estonia/173671/2023 cs 2023‑03‑04 BV 2023‑05‑15 2023‑09‑27 cs V1A.3a.2 2023‑06‑21 17820245 Normal inhibition Normal inhibition Normal inhibition B/Estonia/173671/2023 cs 2023‑03‑04 BV 2023‑05‑15 2023‑09‑27 MDCK1 V1A.3a.2 2023‑10‑24 18430766 Normal inhibition Normal inhibition Normal inhibition B/Estonia/KL329/2023 cs 2023‑03‑02 BV 2023‑05‑15 Failed sequence – not cultured cs no sequence B/Estonia/173795/2023 cs 2023‑02‑27 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820244 B/Estonia/173588/2023 cs 2023‑02‑27 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820243 B/Estonia/173587/2023 cs 2023‑02‑27 BV 2023‑05‑15 2023‑08‑15 cs V1A.3a.2 2023‑06‑21 17820242 Normal inhibition Normal inhibition B/Estonia/173587/2023 cs 2023‑02‑27 BV 2023‑05‑15 2023‑08‑15 MDCK1 V1A.3a.2 2023‑09‑06 18226853 Normal inhibition Normal inhibition B/Estonia/173577/2023 cs 2023‑02‑26 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820241 B/Estonia/173794/2023 cs 2023‑02‑24 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820240 B/Estonia/173584/2023 cs 2023‑02‑23 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820239 B/Estonia/173583/2023 cs 2023‑02‑22 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820238 B/Estonia/173581/2023 cs 2023‑02‑22 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820237 B/Estonia/173580/2023 cs 2023‑02‑22 BV 2023‑05‑15 2023‑08‑15 cs V1A.3a.2 2023‑06‑21 17820234 Normal inhibition Normal inhibition B/Estonia/173580/2023 cs 2023‑02‑22 BV 2023‑05‑15 2023‑08‑15 MDCK1 V1A.3a.2 2023‑09‑06 18226854 Normal inhibition Normal inhibition B/Estonia/173582/2023 cs 2023‑02‑21 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820235 B/Estonia/173498/2023 cs 2023‑02‑20 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820222 B/Estonia/173497/2023 cs 2023‑02‑20 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820246 B/Estonia/173495/2023 cs 2023‑02‑17 BV 2023‑05‑15 Virus not recovered cs V1A.3a.2 2023‑06‑21 17820233 B/Estonia/173493/2023 cs 2023‑02‑16 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820232 B/Estonia/173492/2023 cs 2023‑02‑15 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820231 B/Estonia/173490/2023 cs 2023‑02‑15 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820230 B/Estonia/173429/2023 cs 2023‑02‑15 BV 2023‑05‑15 2023‑08‑15 cs V1A.3a.2 2023‑06‑21 17820229 Normal inhibition Normal inhibition B/Estonia/173429/2023 cs 2023‑02‑15 BV 2023‑05‑15 2023‑08‑15 MDCK1 V1A.3a.2 2023‑09‑06 18226855 Normal inhibition Normal inhibition B/Estonia/KL257/2023 cs 2023‑02‑13 BV 2023‑05‑15 Failed sequence – not cultured cs no sequence B/Estonia/173317/2023 cs 2023‑02‑03 BV 2023‑05‑15 2023‑08‑15 cs V1A.3a.2 2023‑06‑21 17820228 Normal inhibition Normal inhibition B/Estonia/173317/2023 cs 2023‑02‑03 BV 2023‑05‑15 2023‑08‑15 MDCK1 V1A.3a.2 2023‑09‑06 18226856 Normal inhibition Normal inhibition B/Estonia/KL190/2023 cs 2023‑02‑02 BV 2023‑05‑15 Identical sequence – not cultured cs V1A.3a.2 2023‑06‑21 17820227 B/Estonia/KL183/2023 cs 2023‑01‑31 BV 2023‑05‑15 Failed sequence – not cultured cs no sequence B/Estonia/173183/2023 cs 2023‑01‑27 BV 2023‑05‑15 cs V1A.3a.2 2023‑06‑21 17820226 B/Estonia/173180/2023 cs 2023‑01‑27 BV 2023‑05‑15 Failed sequence – not cultured cs no sequence B/Estonia/173175/2023 cs 2023‑01‑27 BV 2023‑05‑15 cs V1A.3a.2 2023‑06‑21 17820225
26
(continued)
Antigenic characterisation Genetic characterisation Antiviral susceptibility phenotypic testing
Virus name Original passage sent Collection date Type/Subtype Date received HI table date HI comments WIC Passage history Genetic clade Submitted to GISAID EPI Accession Sequencing comments Oseltamivir Zanamivir Baloxavir marboxil
B/Estonia/173173/2023 cs 2023‑01‑27 BV 2023‑05‑15 Failed sequence – not cultured cs no sequence A/Estonia/174173/2023 cs 2023‑04‑16 H1pdm 2023‑05‑15 Virus not recovered cs no sequence A/Estonia/174171/2023 cs 2023‑04‑14 H1pdm 2023‑05‑15 2023‑05‑23 cs 5a.2a 2023‑06‑21 17820192 Normal inhibition Normal inhibition A/Estonia/174171/2023 cs 2023‑04‑14 H1pdm 2023‑05‑15 2023‑05‑23 MDCK1 5a.2a 2023‑07‑20 18008446 Normal inhibition Normal inhibition A/Estonia/174085/2023 cs 2023‑04‑09 H1pdm 2023‑05‑15 Virus not recovered cs no sequence A/Estonia/KL487/2023 cs 2023‑04‑05 H1pdm 2023‑05‑15 Virus not recovered cs no sequence A/Estonia/173780/2023 cs 2023‑03‑07 H1pdm 2023‑05‑15 2023‑05‑23 cs 5a.2a 2023‑06‑21 17820190 Normal inhibition Normal inhibition A/Estonia/173780/2023 cs 2023‑03‑07 H1pdm 2023‑05‑15 2023‑05‑23 MDCK1 5a.2a 2023‑07‑20 18008445 Normal inhibition Normal inhibition A/Estonia/173716/2023 cs 2023‑03‑07 H1pdm 2023‑05‑15 Virus not recovered cs no sequence A/Estonia/173652/2023 cs 2023‑03‑02 H1pdm 2023‑05‑15 2023‑05‑23 cs 5a.2a 2023‑06‑21 17820193 Normal inhibition Normal inhibition A/Estonia/173652/2023 cs 2023‑03‑02 H1pdm 2023‑05‑15 2023‑05‑23 MDCK1 5a.2a 2023‑07‑20 18008538 Normal inhibition Normal inhibition A/Estonia/KL318/2023 cs 2023‑02‑27 H1pdm 2023‑05‑15 2023‑06‑01 cs no sequence Normal inhibition Normal inhibition A/Estonia/KL318/2023 cs 2023‑02‑27 H1pdm 2023‑05‑15 2023‑06‑01 MDCK2 5a.2a 2023‑06‑21 17820159 Normal inhibition Normal inhibition A/Estonia/173557/2023 cs 2023‑02‑21 H1pdm 2023‑05‑15 2023‑05‑23 cs 5a.2a 2023‑06‑21 17820194 Normal inhibition Normal inhibition A/Estonia/173557/2023 cs 2023‑02‑21 H1pdm 2023‑05‑15 2023‑05‑23 MDCK1 5a.2a 2023‑07‑20 18008539 Normal inhibition Normal inhibition A/Estonia/KL262/2023 cs 2023‑02‑14 H1pdm 2023‑05‑15 2023‑05‑23 cs 5a.2a 2023‑06‑21 17820195 Normal inhibition Normal inhibition A/Estonia/KL262/2023 cs 2023‑02‑14 H1pdm 2023‑05‑15 2023‑05‑23 MDCK1 5a.2a 2023‑07‑20 18008531 Normal inhibition Normal inhibition A/Estonia/173456/2023 cs 2023‑02‑14 H1pdm 2023‑05‑15 2023‑05‑23 cs 5a.2a 2023‑06‑21 17820191 Normal inhibition Normal inhibition A/Estonia/173456/2023 cs 2023‑02‑14 H1pdm 2023‑05‑15 2023‑05‑23 MDCK1 5a.2a 2023‑07‑20 18008535 Normal inhibition Normal inhibition A/Estonia/173432/2023 cs 2023‑02‑14 H1pdm 2023‑05‑15 2023‑05‑23 cs no sequence Failed Failed A/Estonia/173432/2023 cs 2023‑02‑14 H1pdm 2023‑05‑15 2023‑05‑23 MDCK1 5a.2a 2023‑07‑20 18008534 Failed Failed A/Estonia/KL248/2023 cs 2023‑02‑10 H1pdm 2023‑05‑15 Virus not recovered cs 5a.2a 2023‑06‑21 17820200 A/Estonia/173339/2023 cs 2023‑02‑09 H1pdm 2023‑05‑15 Virus not recovered cs no sequence A/Estonia/173338/2023 cs 2023‑02‑09 H1pdm 2023‑05‑15 2023‑08‑01 cs 5a.2a 2023‑06‑21 17820196 Normal inhibition Normal inhibition Normal inhibition A/Estonia/173338/2023 cs 2023‑02‑09 H1pdm 2023‑05‑15 2023‑08‑01 MDCK2 no sequence Normal inhibition Normal inhibition Normal inhibition A/Estonia/173321/2023 cs 2023‑02‑07 H1pdm 2023‑05‑15 2023‑07‑25 cs 5a.2a 2023‑06‑21 17820197 Normal inhibition Normal inhibition Normal inhibition A/Estonia/173321/2023 cs 2023‑02‑07 H1pdm 2023‑05‑15 2023‑07‑25 MDCK1 5a.2a 2023‑08‑31 18167241 Normal inhibition Normal inhibition Normal inhibition A/Estonia/173293/2023 cs 2023‑02‑07 H1pdm 2023‑05‑15 Virus not recovered cs no sequence A/Estonia/173320/2023 cs 2023‑02‑05 H1pdm 2023‑05‑15 2023‑07‑25 cs no sequence Normal inhibition Normal inhibition Normal inhibition A/Estonia/173320/2023 cs 2023‑02‑05 H1pdm 2023‑05‑15 2023‑07‑25 MDCK1 5a.2a 2023‑08‑31 18167242 Normal inhibition Normal inhibition Normal inhibition A/Estonia/173262/2023 cs 2023‑02‑05 H1pdm 2023‑05‑15 Virus not recovered cs no sequence A/Estonia/173318/2023 cs 2023‑02‑04 H1pdm 2023‑05‑15 2023‑08‑08 cs 5a.2a 2023‑06‑21 17820198 Normal inhibition Normal inhibition Normal inhibition A/Estonia/173318/2023 cs 2023‑02‑04 H1pdm 2023‑05‑15 2023‑08‑08 MDCK1 5a.2a 2023‑08‑31 18167501 Normal inhibition Normal inhibition Normal inhibition A/Estonia/173244/2023 cs 2023‑02‑02 H1pdm 2023‑05‑15 Virus not recovered cs no sequence A/Estonia/KL184/2023 cs 2023‑01‑31 H1pdm 2023‑05‑15 cs no sequence A/Estonia/173282/2023 cs 2023‑01‑31 H1pdm 2023‑05‑15 cs 5a.2a 2023‑06‑21 17820199 A/Estonia/173168/2023 cs 2023‑01‑28 H1pdm 2023‑05‑15 cs 5a.2a.1 2023‑06‑21 17820201 A/Estonia/173775/2023 cs 2023‑03‑13 H3 2023‑05‑15 Virus not recovered cs no sequence A/Estonia/173741/2023 cs 2023‑03‑08 H3 2023‑05‑15 2023‑05‑26 cs 2a.1b 2023‑06‑21 17820181 Normal inhibition Normal inhibition A/Estonia/173741/2023 cs 2023‑03‑08 H3 2023‑05‑15 2023‑05‑26 SIAT1 2a.1b 2023‑06‑21 17820177 Normal inhibition Normal inhibition A/Estonia/173616/2023 cs 2023‑03‑06 H3 2023‑05‑15 2023‑05‑26 cs 2a.1b 2023‑06‑21 17820189 Normal inhibition Normal inhibition A/Estonia/173616/2023 cs 2023‑03‑06 H3 2023‑05‑15 2023‑05‑26 SIAT1 2a.1b 2023‑06‑21 17820178 Normal inhibition Normal inhibition A/Estonia/173645/2023 cs 2023‑03‑02 H3 2023‑05‑15 2023‑05‑26 cs 2a.1b 2023‑06‑21 17820182 Normal inhibition Normal inhibition A/Estonia/173645/2023 cs 2023‑03‑02 H3 2023‑05‑15 2023‑05‑26 SIAT1 2a.1b 2023‑07‑20 18008505 Normal inhibition Normal inhibition A/Estonia/173578/2023 cs 2023‑02‑25 H3 2023‑05‑15 2023‑05‑26 cs 2a.1b 2023‑06‑21 17820179 Normal inhibition Normal inhibition A/Estonia/173578/2023 cs 2023‑02‑25 H3 2023‑05‑15 2023‑05‑26 SIAT1 2a.1b 2023‑07‑20 18008507 Normal inhibition Normal inhibition A/Estonia/173486/2023 cs 2023‑02‑19 H3 2023‑05‑15 2023‑05‑26 cs 2a.1b 2023‑06‑21 17820183 Normal inhibition Normal inhibition A/Estonia/173486/2023 cs 2023‑02‑19 H3 2023‑05‑15 2023‑05‑26 SIAT1 2a.1b 2023‑07‑20 18008499 Normal inhibition Normal inhibition A/Estonia/173486/2023 cs 2023‑02‑19 H3 2023‑05‑15 2023‑05‑26 sequence not submitted SIAT2 2a.1b Normal inhibition Normal inhibition A/Estonia/KL283/2023 cs 2023‑02‑15 H3 2023‑05‑15 2023‑05‑26 cs 2b 2023‑06‑21 17820184 Normal inhibition Normal inhibition A/Estonia/KL283/2023 cs 2023‑02‑15 H3 2023‑05‑15 2023‑05‑26 SIAT1 2b 2023‑07‑27 18044315 Normal inhibition Normal inhibition A/Estonia/173489/2023 cs 2023‑02‑14 H3 2023‑05‑15 2023‑05‑26 cs no sequence A/Estonia/173489/2023 cs 2023‑02‑14 H3 2023‑05‑15 2023‑05‑26 SIAT1 no sequence A/Estonia/173253/2023 cs 2023‑02‑02 H3 2023‑05‑15 2023‑05‑26 cs 2b 2023‑06‑21 17820185 Normal inhibition Normal inhibition A/Estonia/173253/2023 cs 2023‑02‑02 H3 2023‑05‑15 2023‑05‑26 SIAT1 2b 2023‑07‑20 18007339 Normal inhibition Normal inhibition A/Estonia/173181/2023 cs 2023‑01‑30 H3 2023‑05‑15 Virus not recovered cs 2a.1b 2023‑06‑21 17820186 A/Estonia/173182/2023 cs 2023‑01‑27 H3 2023‑05‑15 Virus not recovered cs no sequence A/Estonia/173171/2023 cs 2023‑01‑24 H3 2023‑05‑15 Virus not recovered cs 2a.1b 2023‑06‑21 17820187 A/Estonia/173170/2023 cs 2023‑01‑24 H3 2023‑05‑15 Virus not recovered cs 2b 2023‑06‑21 17820188 A/Estonia/173097/2023 cs 2023‑01‑23 H3 2023‑05‑15 2023‑05‑26 cs no sequence Normal inhibition Normal inhibition A/Estonia/173097/2023 cs 2023‑01‑23 H3 2023‑05‑15 2023‑05‑26 SIAT1 2b 2023‑07‑20 18007338 Normal inhibition Normal inhibition A/Estonia/173033/2023 cs 2023‑01‑17 H3 2023‑05‑15 2023‑05‑26 cs 2b 2023‑06‑21 17820180 Normal inhibition Normal inhibition A/Estonia/173033/2023 cs 2023‑01‑17 H3 2023‑05‑15 2023‑05‑26 SIAT1 2b 2023‑07‑20 18007337 Normal inhibition Normal inhibition
27
Summary of the latest WHO Influenza Vaccine Compositionmeetings Genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collec‑ tion dates after 31 January 2023 until 31 August 2023 informed the WHO influenza vaccine composition meeting (VCM) in September 2023 when recommendations were made for the southern hemisphere (SH) 2024 influenza season. At the September 2023 VCM it was recommended to change the A(H1N1)pdm09 and A(H3N2) vaccine components for the 2024 SH season. Previously, at the February 2023 VCM, which focused on data from viruses collected after 31 August 2022 until 31 January 2023, it was also recommended to change the A(H1N1)pdm09 vaccine component for the 2023‑2024 northern hemisphere (NH) season.
It was recommended that vaccines for use in the 2024 southern hemisphere influenza season contain the following:
Trivalent: Egg‑based Vaccines
• an A/Victoria/4897/2022 (H1N1)pdm09‑like virus; • an A/Thailand/8/2022 (H3N2)‑like virus; and • a B/Austria/1359417/2021 (B/Victoria lineage)‑like virus.
Trivalent: Cell‑ or recombinant‑based Vaccines
• an A/Wisconsin/67/2022 (H1N1)pdm09‑like virus; • an A/Massachusetts/18/2022 (H3N2)‑like virus; and • a B/Austria/1359417/2021 (B/Victoria lineage)‑like virus.
Quadrivalent: egg‑ or cell culture‑ or recombinant‑based vaccines
Above 3 components; and a B/Phuket/3073/2013 (B/Yamagata lineage)‑like virus.
It was recommended that vaccines for use in the 2023‑24 northern hemisphere influenza season contain the fol‑ lowing:
Trivalent: Egg‑based Vaccines
• an A/Victoria/4897/2022 (H1N1)pdm09‑like virus; • an A/Darwin/9/2021 (H3N2)‑like virus; and • a B/Austria/1359417/2021 (B/Victoria lineage)‑like virus.
Trivalent: Cell‑ or recombinant‑based Vaccines
• an A/Wisconsin/67/2022 (H1N1)pdm09‑like virus; • an A/Darwin/6/2021 (H3N2)‑like virus; and • a B/Austria/1359417/2021 (B/Victoria lineage)‑like virus.
Quadrivalent: egg‑ or cell culture‑ or recombinant‑based vaccines
Above 3 components; and a B/Phuket/3073/2013 (B/Yamagata lineage)‑like virus.
28
ANNEX Genetic clade classification of recent seasonal viruses
Influenza type A viruses
A(H1N1)pdm09 All A(H1N1)pdm09 viruses detected recently descend from 6B.1A.5a. The new nomenclature drops the prefix 6B.1A. Clade 5a has split into two antigenically distinct clusters:
• Clade 5a.1 o signature amino acid substitutions D187A, Q189E o Vaccine virus: A/Guangdong-Maonan/SWL1536/2019
Signature amino acid substitutions are described against A/Guangdong-Maonan/SWL1536/2019 from here onwards.
• Clade 5a.2 o signature amino acid substitutions K130N, N156K, A187D, L161I and V250A o Vaccine virus: A/Victoria/2570/2019 o Clade 5a.2a o signature amino acid substitutions Clade 5a.2 + K54Q, A186T, E224A, R259K and K308R o Vaccine virus: A/Sydney/5/2021
Clade 5a.2a.1 • signature amino acid substitutions Clade 5a.2a + P137S, K142R, D260E,
T277A • Vaccine virus: A/Wisconsin/67/2022 • Subclade with T216A. Vaccine virus: A/Victoria/4897/2022
A(H3N2) All viruses detected recently belong to clade 3C.2a1b.2a which has split into two clades, 3C.2a1b.2a.1 and 3C.2a1b.2a.2. The new nomenclature drops the prefix 3C.2a1b.2a, renaming these clades as 1 and 2. Gain/Loss of glycosylation is represented by +CHO/-CHO.
• Clade 1 o Signature amino acid substitutions G186S, S198P o Reference virus: A/Tasmania/503/2020 o Clade 1a
Signature amino acid substitutions Clade 1 + K171N Vaccine virus: A/Cambodia/e0826360/2020
Signature amino acid substitutions are described against A/Cambodia/e0826360/2020 from here onwards
Clade 1a.1
• Signature amino acid substitutions Clade 1a + I48T • Reference virus: A/Guizhou-Liuzhite/326/2022
• Clade 2 o Signature amino acid substitutions Y159N, T160I (-CHO), L164Q, N171K, S186D, D190N,
P198S o Reference virus: A/Norway/29511/2021 o Clade 2a
Signature amino acid substitutions Clade 2 + H156S Vaccine virus: A/Darwin/9/2021 Clade 2a.1
• Signature amino acid substitutions Clade 2a + D53G, D104G, K276R • Reference virus: A/Slovenia/8720/2022 • Clade 2a.1a
o Signature amino acid substitutions Clade 2a.1 + L157I o Reference virus: A/Maryland/02/2021
• Clade 2a.1b o Signature amino acid substitutions Clade 2a.1 + I140K, R299K o Reference virus: A/Catalonia/NSVH161512067/2022
Clade 2a.2 • Signature amino acid substitutions Clade 2a + D53G, R201K, S219Y • Reference virus: A/Poland/97/2022
Clade 2a.3 • Signature amino acid substitutions Clade 2a + D53N, N96S (+CHO), I192F • Reference virus: A/Norway/24873/2021 • Clade 2a.3a
o Signature amino acid substitutions Clade 2a.3 + E50K o Reference virus: A/Finland/402/2023 o Clade 2a.3a.1
Signature amino acid substitutions Clade 2a.3a + I140K, I223V
Vaccine virus: A/Thailand/8/2022 • Clade 2a.3b
o Signature amino acid substitutions Clade 2a.3 + I140M o Reference virus: A/Sydney/732/2022
o Clade 2b Signature amino acid substitutions Clade 2 + E50K, F79V, I140K Reference virus: A/Thuringen/10/2022
Influenza type B viruses
B/Victoria/2/87 lineage Signature amino acid substitutions are described against B/Brisbane/60/2008. In recent months, only viruses derived from clade V1A.3a.2 have circulated.
• Clade V1A.3 o Signature amino acid substitutions I117V, N129D, K136E, del(162-164) o Vaccine virus: B/Washington/02/2019 o Clade V1A.3a
Signature amino acid substitutions Clade V1A.3 + N150K, G184E, N197D (+CHO) and R279K
Reference virus: B/Croatia/7789/2019 Clade V1A.3a.1
• Signature amino acid substitutions Clade V1A.3a + V220M, P241Q • Reference virus: B/Cote d’Ivoire/948/2020
Clade V1A.3a.2 • Signature amino acid substitutions Clade V1A.3a + A127T, P144L, N150K,
G184E, N197D(-CHO), K203R, R279K • Vaccine virus: B/Austria/1359417/2021 • Subclade with D197E. Reference virus: B/Connecticut/01/2021 • Subclade with D197E, E183K. Reference virus:
B/Catalonia/2279261NS/2023 • Subclade with E128K, A154E, S208P. Reference virus:
B/Moldova/2030521/2023
B/Yamagata/16/88 lineage Genetic clade Y3 viruses, represented by the vaccine virus B/Phuket/3073/2013, have circulated in recent years. However, very few detections have been reported recently and no viruses with collection dates after March 2020 have been made available for detailed characterisation.